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ABSTRACT

Non-insulin dependent diabetes mellitus (NIDDM) is a heterogeneous
disease arising from metabolic defects in insulin secretion and insulin action.
The inability of insulin to trigger full metabolic responses results in impaired
glucose transport, which elicits compensatory hyperinsulinemia with
increased lipogenesis. In order to identify the molecular defects responsible
for insulin resistance, we have investigated three different model systems:
the ability of sulfonylurea receptor (SUR) ligands to modify insulin
regulated events in cultured rodent adipocytes; the ability of agouti and/or
agouti related polypeptide (AGRP) to modify insulin-regulated events; and
the regulation of the activity and amount of the HNF-1α transcription factor,
mutations of which result in a subset of NIDDM, by variations in glucose
concentration. Because the results of animal studies are often obscured by
the interactions between multiple tissues, we have used model cell lines in
culture to investigate these systems.

In obese Zucker rats, diazoxide decreases hyperinsulinemia and
lipogenesis while improving the insulin sensitivity of glucose transport in
adipose tissue. The opposing effects on glucose transport and lipogenesis
iv

suggest that diazoxide might have extrapancreatic effects that modify insulin
signaling in adipose tissues. Accordingly, we have investigated the effect of
diazoxide and glibenclamide (another SUR ligand) on glucose transport and
insulin signaling in cultured 3T3-L1 adipocytes. Our results suggest that
diazoxide has no direct effect on insulin signaling and glucose transport. In
contrast, glibenclamide exhibited dual effects on glucose uptake. Acute
exposure to glibenclamide resulted in inhibition of glucose uptake, while
long-term incubation with glibenclamide enhanced glucose uptake
independent of insulin action. Diazoxide was unable to antagonize either
effect of glibenclamide, suggesting that the effects of glibenclamide were
not mediated by the sulfonylurea receptor.

In the yellow mouse obesity syndromes, ectopic expression of the
Agouti gene results in late-onset obesity and type II diabetes. Agouti
overexpressed in hypothalamus mimics the natural action of AGRP, which
antagonizes α-Melanocyte-Stimulating Hormone (α-MSH) at the
Melanocortin-4-recptor (MC-4-R) that controls feeding behavior and
metabolism. Although this antagonism in the central nervous system is
sufficient to cause the agouti phenotype, a calcium-dependent mechanism
for agouti’s actions in peripheral tissues has been proposed to account for
v

enhanced lipogenesis and insulin secretion. To better understand the
molecular mechanisms utilized by agouti to modify insulin sensitivity, we
have investigated the effects of agouti and AGRP on insulin signaling and its
biological responses in cultured 3T3-L1 adipocytes. We observed no effects
of either agouti or AGRP on glucose uptake or FAS activity. In contrast,
insulin stimulates glucose uptake in a dose-dependent manner and induces
fatty acid synthase (FAS) activity as previously reported. In addition, the
insulin-stimulated protein tyrosine phosphorylation and activation of
downstream kinases were not affected by either agouti or AGRP.

Mutations in HNF-1 genes result in MODY3 (a subtype of NIDDM)
that are characterized by pancreatic β-cell dysfunction. The diminished
insulin storage and secretion are consistent with the reduced HNF-1 activity
that regulates the transcription of insulin genes and genes involved in
glycolysis and glucose transport. Reduction in HNF-1 activity and protein
has been observed in the livers of type I diabetic animals. Restoring
euglycemia without affecting insulin levels rescued hepatic HNF-1 activity
and protein in these animals. Accordingly, we investigated whether
hyperglycemia also suppresses HNF-1 activity in the type II diabetic
animals. Examination of hepatonuclear extracts prepared from the obese
vi

Zucker rats revealed that HNF-1 binding activity was reduced. However, the
reduction is not due to diminished HNF-1 protein levels as previously
reported in the type I diabetic animals. Incubating Fao rat hepatoma cells
with high concentrations of glucose resulted in a similar decrease in HNF-1
binding activity, with no changes in HNF-1 protein levels. The results with
the hepatoma cells reflect the observation made with the obese Zucker rats
and point to nutritional regulation of HNF-1 activity in the liver.
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CHAPTER I
INTRODUCTION
Non-insulin-dependent Diabetes Mellitus
Diabetes mellitus is a metabolic disease in which dysregulation of
carbohydrate and lipid metabolism by insulin leads to complications
including heart disease, stroke, kidney failure, blindness and nerve damage,
causing prevalent morbidity and mortality in the human population (43, 74,
127, 128, 141). Based upon distinct pathophysiology, there are two main

categories of the disease: type I diabetes and type II diabetes (75, 127). Type I
diabetic patients are dependent on exogenous insulin as a result of the
autoimmune destruction of the pancreatic β-cells that produce insulin (127).
This is sometimes referred to as insulin-dependent diabetes mellitus
(IDDM). Loss of insulin results in elevated plasma glucose that results in
organ damage over time. Type II diabetes, also known as non-insulindependent diabetes mellitus (NIDDM), is the most common form of diabetes
in the Western world, accounting for 90-95% of all cases (74, 75). In the
United States more than 14 million Americans are estimated to have the
disease and one third of these are believed to be undiagnosed, according to
the American Diabetes Association (136). Patients who suffer from type II
1

diabetes display a characteristic combination of defects in insulin secretion
and insulin action (Figure 1-1, please see Appendix for all figures) (75).

The inability of insulin to trigger full metabolic responses in its target
tissues is referred to as insulin resistance (Figure 1-1). The condition usually
occurs in people who are over 45 years of age, overweight and lead a
sedentary lifestyle. As fully one third of the American population is now
considered obese and obesity in children is escalating dramatically (136), the
strong association of obesity with type II diabetes has further increased the
risk of the disease in future generations (43). Intensive studies in the past
decade has led to much progress in understanding the molecular pathways of
insulin action and various aspects of type II diabetes. However, the
molecular mechanisms that relate increased adiposity to impaired insulin
actions are still not fully understood.

Metabolic Actions of Insulin
Insulin and glucagon are the two major hormones that, acting in an
opposing manner, regulate glucose homeostasis. In response to high levels
of serum glucose (Figure 1-2), insulin is released by pancreatic β-cells to
stimulate glucose uptake, utilization and storage in fat and muscle (Figure 12

3), while suppressing the hepatic output of glucose. In muscle, glucose is
converted to glycogen as an energy storage molecule or oxidized to generate
ATP. In adipocytes, glucose is stored after metabolism primarily as lipids.
Insulin activates glycogen synthase, glycolytic enzymes such as pyruvate
kinase and lipogenic enzymes such as fatty acid synthase (FAS),
respectively.

Uptake is the rate-limiting step for glucose utilization and storage.
Insulin stimulates the transport of glucose into muscle and fat cells by
mobilizing the intracellular pool of glucose transporter 4 (Glut4) so that it is
presented on the plasma membrane (Figure 1- 4) (1, 29, 97). Among the
family of mammalian glucose transporter proteins, Glut4 is unique in that it
is predominantly expressed in muscle and adipose tissues. In resting cells, it
is highly sequestered in intracellular compartments. The proportion that is
intracellular in unstimulated cells is greater than 95 % of the total. Without
this sequestration, insulin would not be able to acutely regulate glucose
uptake (57).

The insulin-regulated exocytosis of Glut4 requires
phosphatidylinositol-3 kinase (PI-3K) activity (Figure 1-5) (7). Upon insulin
3

binding to its heterotetrameric (α2β2) receptors, the receptor tyrosine kinase
catalyzes intramolecular transphosphorylation on specific tyrosine residues,
leading to increased tyrosine kinase activity toward cellular substrates.
Subsequent tyrosine phosphorylation on proteins of the insulin receptor
substrate family (IRS-1~4)) and other adaptor proteins creates multiple
recognition sites for Src Homology 2 (SH2) domain-containing proteins
such as the regulatory subunit (p85) of PI-3 Kinase. The association of p85
with IRS proteins activates PI-3 kinase, generating phosphatidylinositol
3,4,5 triphosphate (PIP3). Increased PIP3 activates a serine/threonine kinase
cascade, including phosphoinositide-dependent kinase 1 (PDK 1) that
phosphorylates Akt (PKB) and the atypical protein kinases C ζ and λ (29,
138, 146).

The PI-3K inhibitor wortmannin blocks many of the metabolic actions
of insulin, including the effects of the hormone on glucose transport and
glycogen synthase (GS) activities (29, 125, 131). Moreover, both the
inactivation of glycogen synthase kinase-3 (GSK-3) and the activation of
protein phosphatase 1(PP1) are blocked by wortmannin (16, 62). However,
the activation of PI-3K alone is not sufficient for insulin action, since other
hormones and adhesion molecules can stimulate PI-3K activity without
4

reproducing the metabolic effects of insulin (52, 150). Furthermore, cellpermeable derivatives of PIP3 do not fully mimic the effects of insulin on
glucose transport (69). Thus, although the PI-3K pathway is necessary, there
is at least one additional pathway required for glucose transport regulation
by insulin.

Obesity and Insulin Resistance
In patients with type II diabetes, insulin is less capable of stimulating
the uptake of glucose into muscle and fat, and of inhibiting the production of
glucose by the liver. The pleiotropic actions of insulin are impaired to
variable extents, collectively known as insulin resistance (114, 133). The
ability of insulin to stimulate glucose uptake is more profoundly affected
than its ability to promote lipogenesis (74). Manifesting such discordant
actions of insulin, glucose intolerance and obesity are closely associated
with the type II diabetes, but the molecular mechanism underlying the
differential impairments of insulin signaling remains unclear.

Clinical studies have suggested that obesity precedes insulin
resistance in type 2 diabetes (74), indicating that adipose tissue harbors the
primary (earliest) cause of insulin resistance (15). Recent studies using
5

transgenic mice have demonstrated that adipocyte-specific impairment of
glucose uptake is sufficient to cause insulin resistance in fat and other
insulin-sensitive tissues (1). One potential mechanism that the adipocyte
might use to dictate insulin sensitivity in other insulin-sensitive tissues is to
secrete hormones such as leptin and tumor necrosis factor-α (TNF-α), which
affect insulin signaling through endocrine action (43).

TNF-α levels are elevated in states of obesity, perhaps reflecting
increased adiposity (135-137). The adipocyte-derived cytokine exerts
catabolic effects on adipocytes, blocking lipid synthesis and lipoprotein
lipase expression, while activating lipolysis (136, 137). It can also block or
reverse differentiation of fibroblastic precursors into adipocytes (135).
Hotamisligil et al have suggested that excessive TNF-α might mediate
obesity-induced insulin resistance (58-61). In vitro studies demonstrated that
TNF-α can impair insulin signaling by stimulating the serine
phosphorylation of IRS proteins, leading to decreased tyrosine
phosphorylation and PI-3K association (59, 61). However, the kinases that
catalyze the inhibitory serine phosphorylation of IRS proteins remain
unknown.
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Leptin acts primarily in the ventromedial hypothalamus (43, 80).
Lesions in this region of the brain are known to result in hyperinsulinemia
and insulin resistance, implicating leptin or other centrally acting peptides in
the control of insulin sensitivity (37). Moreover, leptin improves insulin
sensitivity in normal rodents independent of food intake and profoundly
impacts different neuroendocrine pathways that modulate insulin actions (9,
40, 80). However, leptin receptors are also found in many insulin target

tissues (41, 80), and the hormone has been reported to increase fatty acid
oxidation, suggesting the possibility of a direct effect on the peripheral
tissues (43, 90). Therefore, there is precedence that adipocyte-derived
hormones may have autocrine or paracrine functions in local tissues while
also acting centrally to communicate the metabolic status of peripheral
tissues to the brain.

Agouti, AGRP and the Yellow Mouse Obesity Syndrome
The murine Agouti gene is normally involved in coat color regulation
in wild-type mice. Expression of agouti in the hair follicles during early
postnatal development causes a switch from black to yellow pigment
synthesis, resulting in a subapical yellow band on otherwise dark hair (104).
Agouti is a paracrine-signaling factor that is secreted by dermal papillae
7

cells, adjacent to melanocytes, and acts within the hair follicle
microenvironment to block melanocortin action (35). Melanocortins such as
α-melanocyte-stimulating hormone (α-MSH) and adrenocorticotropic
hormone (ACTH) are the natural ligands for a family of G protein-coupled
melanocortin receptors (MC-R), of which five isoforms are presently known
(46, 47, 63, 102, 103). MC1-R is the melanocyte-stimulating hormone receptor

expressed in melanocytes and has a physiological role in pigmentation (103).
MC4-R is expressed mainly in the brain and has been implicated in the
regulation of feeding behavior and metabolism (46, 47, 63). Binding of αMSH to the receptor triggers elevation of cAMP levels and activation of
tyrosinase, the rate-limiting enzyme of melanogenesis resulting in eumelanin
production (35). In the presence of agouti the opposite is true; eumelanin
synthesis is shut down and the default pathway that has phaeomelanin as the
final product is activated. Therefore, agouti expression controls the relative
amount and distribution of eumelanin (brown/black) and phaeomelanin
(red/yellow) pigments in the mammalian coat (104).

Aberrant expression of Agouti in mice results in obesity and
peripheral insulin resistance similar to the conditions found in human type II
diabetes (104). Dominant mutations at the Agouti locus, such as the lethal
8

yellow (Ay/a) and viable yellow (Avy/a) result in the yellow obesity
syndrome, characterized by yellow coat color as well as late onset obesity
associated with hyperphagia, increased linear growth, non-insulin-dependent
diabetes and an increased propensity for developing tumors (161). Genetic
analysis has shown that Ay is in fact the result of a chromosomal
rearrangement in which the promoter and the first non-coding exon of a
closely linked gene, Raly, get spliced to exons of the wild-type agouti gene
(98). The Agouti gene, now under the control of the relaxed Raly promoter

and devoid of temporal and regional restrictions, becomes ectopically
expressed. Overexpression of Agouti in multiple tissues is therefore the
cause of the Ay phenotype. This conclusion is further supported by the
ability of agouti, under the control of a β-actin promoter, to recapitulate the
Ay phenotype in transgenic animals (82). The agouti protein is a potent
melanocortin antagonist (78, 93, 151) (Figure 1-6). Pharmacological studies of
murine agouti protein conclude that its mechanism of action is a classical
competitive antagonism of melanocortin receptors (78, 93, 151). Structurally,
agouti displays the characteristics of a secreted protein having a hydrophobic
signal peptide and lacking any transmembrane domains. Within the encoded
131 amino acids, the major structural features of the mature protein are a
highly basic N-terminal region, a Proline-rich central domain, and a C9

terminal domain rich in Cysteine residues (19) (Figure 1-7A). Biochemical
analysis of the agouti protein shows that it is highly glycosylated and very
stable to thermal denaturation (151). The spacing pattern of the 10 Cysteine
residues present in the C-terminus is similar to the ordering of conserved
Cysteine residues in invertebrate neurotoxins, suggesting a conserved threedimensional motif (35) (Figure 1-7B). Based on this structural similarity it
has been postulated that all Cysteine residues of the Agouti protein are
engaged in disulfide bonds (151). In addition, a truncated version of Agouti,
residues 83–131, is known to be as potent an antagonist as the full-length
protein (151). The Cysteine-rich C terminus is, therefore, sufficient for
effective antagonism of melanocortin in vitro as well as in vivo (113, 151).

Agouti was the first obesity gene to be cloned (104). The agoutirelated polypeptide (AGRP) was found recently to share striking similarities
in structure and function but to have a completely different expression
pattern (35). Although the obesity appears to be caused by agouti's effect in
the hypothalamus that controls feeding behavior, the molecular mechanism
linking obesity to peripheral insulin resistance is still not fully understood.
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Pancreatic Action of Sulfonylureas and Diazoxide
Sulfonylureas such as glibenclamide are widely used as oral
hypoglycemic drugs in the treatment of type 2 diabetes (87). Glibenclamide
increases insulin secretion by directly closing the ATP-sensitive K+ channels
in pancreatic β-cells (Figure 1-2) (55, 143) causing membrane depolarization
and opening of the voltage-dependent Ca2+ channels (VDCCs). This allows
Ca2+ influx and the resultant rise in intracellular Ca2+ concentration ([Ca2+]i)
triggers insulin secretion (8, 25). Diazoxide, in contrast, opens the K+
channels and consequently inhibits the secretion of insulin by the pancreas
(143). In addition to reducing circulating insulin, diazoxide treatments have

been shown to result in changes in insulin sensitivity in peripheral tissues of
human and rodent models of type II diabetes (2-5). Although the therapeutic
effects of diazoxide were attributed to its action in the pancreas, several lines
of evidence suggest that an extrapancreatic action of diazoxide on insulin
signaling is likely to exist.

Anti-obesity Effect of Diazoxide
Hyperinsulinism and insulin resistance are characteristic findings in
obese subjects (5, 74). Obesity in both humans and experimental animals is
associated with a reduced number of insulin receptors and a decreased
11

insulin-mediated glucose disposal, whereas sensitivity to insulin's
antilipolytic action is unaltered (3).

Alemzadeh et al reported that diazoxide exerts an anti-obesity effect
in hyperinsulinemic obese Zucker rats and human adults (3-5). Specifically,
diazoxide treatment results in increased insulin receptor binding and glucose
transport while it reduces insulin secretion and insulin sensitivity to the
antilipolytic action of insulin (3, 5).

Although the reduction in plasma insulin levels by diazoxide most
likely leads to the recovery of the number of insulin receptors, the
consequent increase in insulin signaling at the receptor level should result in
increases in both glucose transport and lipid storage. On the contrary,
diazoxide-treated subjects gain less weight while consuming more calories
(3). Therefore, the pancreatic action of diazoxide alone cannot explain the

concurrent but opposite regulation of glucose transport and lipogenesis.

Consistent with the implication of an extrapancreatic action of
diazoxide, a recent study by Shi et al demonstrated that human adipocytes
also express sulfonylurea receptor 1 (SUR1) (132), the pharmacological
12

target of sulfonylurea and diazoxide action in the pancreas. Furthermore,
glibenclamide treatment of isolated human adipocytes causes an increase in
intracellular calcium and lipogenic enzyme activities (132), consistent with
the presence of a sulfonylurea receptor in these cells. As expected, diazoxide
inhibits such increases in lipogenesis, but the direct effect of diazoxide on
glucose transport remains unclear. Thus, the action of diazoxide has not been
reported in rodent adipocytes.

Maturity-onset Diabetes of the Young (MODY)
Maturity-onset diabetes of the young (MODY) is a genetically
heterogeneous monogenic form of non-insulin-dependent diabetes mellitus
(NIDDM), characterized by early onset, usually before 25 years of age and
often in adolescence or childhood, and by autosomal dominant inheritance
(158). Clinical studies have shown that prediabetic MODY subjects have

normal insulin sensitivity but suffer from a defect in glucose-stimulated
insulin secretion, suggesting that pancreatic β-cell dysfunction rather than
insulin resistance is the primary defect in this disorder. Linkage studies have
localized the genes that are mutated in MODY to human chromosomes 20
(MODY1), 7 (MODY2) and 12 (MODY3) (127). MODY2 and MODY3 are
allelic with the genes encoding glucokinase, a key regulator of insulin
13

secretion, and hepatocyte nuclear factor-1α (HNF-1α), a transcription factor
involved in tissue-specific regulation of liver genes but also expressed in
pancreatic islets, insulinoma cell lines and other tissues (20).

Patients with the MODY3 form of NIDDM have mutations in the
gene encoding HNF-1α (159). HNF-1α is a transcription factor that regulates
the tissue-specific expression of several liver genes and is also expressed in
pancreatic islets and other tissues (20). It is not clear how mutations in the
HNF-1α gene can cause diabetes when present on a single allele. It is
possible that a partial deficiency of HNF-1α could lead to β-cell dysfunction
and diabetes. Alternatively, mutations in HNF-1α may cause diabetes by a
dominant-negative mechanism by interfering with the function of wild type
HNF-1α and other proteins that act together with HNF-1α to regulate
transcription. Many HNF-1α gene mutations identified would result in the
synthesis of a mutant protein impaired in DNA-binding or transactivation.
These mutant proteins could form non-productive dimers with the product of
the normal HNF-1α allele or with other proteins such as HNF-1β and impair
the normal function of HNF-1α.
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Transgenic mice that lack HNF-1/α have been generated (117).
Pontoglio et al. compared insulin secretory function in HNF-1α+/-, and
HNF-1α-/- mice with wild type HNF-1α+/+ mice. Blood glucose
concentrations were similar in HNF-1α+/+ and HNF-1α+/- mice, but were
significantly higher in HNF-1α-/- mice. Insulin secretory responses to
glucose in the pancreas from HNF-1α-/- mice were <15% of the values in
the other two groups and were associated with a similar reduction in the
intracellular Ca2+ response (115, 118, 119). These defects were not due to a
decrease in glucokinase or insulin gene transcription. Therefore, the
mutation in the HNF-1a gene in mice probably leads to diabetes due to
alterations in the pathways that regulate β-cell responses to secretagogues
including glucose. Dukes et al. showed that in the HNF-1/α -/- mice the
ATP-sensitive K+ current (KATP) in β-cells is insensitive to suppression by
glucose but normally sensitive to ATP (36). In addition, NAD(P)H
production from glucose oxidation was substantially reduced, and an
inhibitor of glycolytic NADH generation reproduced the mutant phenotype
in normal islets. Therefore, MODY3 seems to result from defective β−cell
glycolytic signaling.
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Research Project Overview
This dissertation is divided into three parts. Each part addresses a
question associated with understanding the biochemical mechanisms
underlying insulin resistance in type II diabetes.

In the first part, we investigated the effects of diazoxide (a KATP
channel opener) and glibenclamide (a KATP channel blocker) on insulin
actions in cultured adipocytes. Several lines of evidence suggest that an
extrapancreatic effect of diazoxide on glucose transport likely exists.
Although the therapeutic effects of diazoxide have been established, the
molecular mechanism underlying the differential modifications of insulin
signaling is still unclear. Second, the effects of diazoxide on post-receptor
insulin signaling are unknown. Because the PI-3 kinase pathway is known to
mediate the metabolic actions of insulin, if the actions of diazoxide on
adipose tissue directly contribute to the improved insulin sensitivity,
activation of molecules within the PI-3 kinase pathway will likely suggest a
molecular mechanism linking insulin signaling to diazoxide action.
Therefore, the purpose of this study was to determine whether the beneficial
effects of diazoxide treatment in vivo can be reproduced in cultured
adipocytes. Also, we sought to determine which molecule (s) within the PI-3
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kinase pathway, if any, might be affected by diazoxide treatment.
Accordingly, our studies were designed to explore the possibilities that: 1)
The effects of diazoxide on glucose transport in adipose tissue are
extrapancreatic; and 2) diazoxide modifies insulin sensitivity by activation
of the PI-3 kinase pathway.

In the second part, we investigated the ability of the Agouti protein or
the agouti-related protein (AGRP) to effect insulin signaling and insulin
action. Although obesity appears to be caused by agouti's effect in the
hypothalamus that controls feeding behavior, the molecular mechanism
linking obesity to peripheral insulin resistance is still not fully understood.
Recently, it was reported that, in cultured adipocytes, agouti stimulates the
transcription of the fatty acid synthase (FAS) gene that is normally regulated
by insulin and that it acts synergistically with insulin to regulate this gene.
This observation raised the possibility that agouti may interact with a
component involved in insulin signaling. Insulin stimulates FAS
transcription through a cascade of kinase activities including PI-3 kinase (PI3K) and its downstream effector, Akt or protein kinase B (PKB).
Interestingly, both PI-3K and PKB activity are required for the insulinstimulated translocation of glucose transporter, which leads to increased
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glucose uptake by the peripheral tissues. Therefore, to investigate whether
agouti interacts and alters insulin-initiated signal transduction, we set out to
test if glucose uptake and PKB activation are affected by agouti treatment.

In the third part, we investigated the effects of hyperglycemia on
HNF-1 expression and DNA-binding activity in livers of obese and lean
Zucker rats treated with diazoxide or left untreated. It has been reported that
hyperglycemia in animals with type I diabetes results in suppression of
hepatic HNF-1 expression and its ability to activate the transcription of the
albumin gene. Given that obese Zucker rats are both hyperglycemic and
hyperinsulinemic, we wondered whether the expression or the activity of
hepatic HNF-1 is affected in the type II diabetic animals. Accordingly, we
sought to examine the expression levels of HNF-1 and albumin in the obese
livers. In addition, we also assessed the DNA-binding activity of HNF-1 in
hepatonuclear extracts for comparison with the data on protein expression.

In order to isolate the effects of hyperglycemia from those of
hyperinsulinemia in the obese Zucker rats, we examined the effects of
diazoxide that significantly attenuates insulin secretion in these animals.
Moreover, we employed cultured hepatoma cells as a model system to
18

address the direct effects of glucose concentrations on HNF-1 expression and
activity.
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CHAPTER II
The Effects of Sulfonylurea Receptor Ligands
on Insulin Signaling in 3T3-L1 Adipocytes
Introduction
Studies on twins and different ethnic groups have indicated that
insulin resistance is genetically predisposed in NIDDM patients and is
induced later in life by environmental factors (75). However, due to the
heterogeneous nature of the disease, it has proven difficult to identify the
susceptibility genes by the methods of molecular genetics (72, 128). Targeted
disruptions of the candidate genes involved in insulin signaling, glucose
metabolism and adipocyte differentiation have all yielded associations with
diabetes, but mutations in these genes only account for 2-5% of the total
NIDDM population (127). Likewise, positional cloning has identified several
rare mutations in the MODY genes only because a distinctive defect in
insulin secretion is associated with these uncommon forms of type II
diabetes (54, 112). Therefore, it is unlikely that one or two major genes are
responsible for the metabolic defects presented in the majority of NIDDM.
Rather, the impaired glucose metabolism probably arises from a number of
genes whose expression and protein activities are modified under
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appropriate environmental conditions. In order to identify the naturally
occurring molecular modifications leading to NIDDM in a defined genetic
background, we have taken the approach that investigates the actions of an
anti-diabetes drug, which specifically reverses insulin resistance in a
monogenic model of NIDDM.

Diazoxide, a sulfonylurea antagonist acting on the pancreatic KATP
channels, has been shown to modify insulin sensitivity in obese Zucker rats
(3, 5). Insulin resistance and compensatory hyperinsulinemia are

characteristic findings in obese subjects. To better understand the
relationships between insulin resistance, hyperinsulinemia and obesity,
Alemzadeh et al ameliorated the hyperinsulinemia in obese Zucker rats and
human adults by treatments with diazoxide, which is known to block insulin
secretion by the pancreas (3-5). As a result, the diazoxide treatments
produced increased insulin receptor binding and glucose transport while
reducing insulin secretion and sensitivity to the antilipolytic action of insulin
in adipocytes.

However, not all of these effects are consistent with the pancreatic
action of diazoxide. Because prolonged exposure to high levels of insulin
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results in the internalization of the insulin receptor (76), the reduction in
plasma insulin levels by diazoxide most likely leads to the recovery of the
insulin receptor number on the cell surface and hence the observed increase
in insulin binding. The consequent increase in insulin signaling (at the
receptor levels) should result in increases in both glucose transport and
lipogenesis. Instead, the diazoxide-treated subjects gained less weight while
consuming more calories (3, 5). Therefore, the pancreatic action of diazoxide
alone cannot explain the concurrent but opposing regulation of glucose
transport and lipogenesis.

Consistent with the implication of an extrapancreatic action of
diazoxide, previous studies on the sulfonylurea action also suggested an
insulin-independent effect of glibenclamide on glucose utilization (6, 17, 32,
39, 65-67, 95, 105, 106, 142, 144, 164). Sulfonylureas are widely used to control

hyperglycemia in type II diabetes (18, 99, 106). The sulfonylurea receptor
(SUR) is an integral component of the pancreatic KATP channels that regulate
insulin secretion (18, 99). The therapeutic effect of sulfonylureas is based
upon their ability to augment insulin release by blocking the KATP channel.
However, several studies have reported that the hypoglycemic effect of
sulfonylureas is still present in patients whose pancreas has completely lost
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the ability to secrete insulin (56, 84, 88, 96, 120). Therefore, a number of in
vitro studies have examined the possibility that sulfonylureas may have
extrapancreatic effects on glucose utilization. These results confirmed the
existence of a stimulatory effect of sulfonylureas on glucose utilization in
peripheral tissues, but the molecular mechanism mediating such stimulation
is still a matter of debate.

The expression of SUR1, the pharmacological target of sulfonylureas
and diazoxide in the pancreas, was recently demonstrated in isolated human
adipocytes (132). Furthermore, the sulfonylurea glibenclamide causes an
increase in intracellular calcium content and lipogenic enzyme activities in
the human adipocytes (132, 140). As expected, diazoxide inhibits the
stimulation of lipogenesis by glibenclamide in these cells. Therefore, it
appears that glibenclamide and diazoxide may directly influence lipid
metabolism through SUR1 in human adipocytes. But it remains unclear
whether glucose transport is also subject to the same kind of regulation by
SUR ligands in adipocytes.

The multiple effects of sulfonylureas on glucose utilization in vitro
suggest potential regulation of insulin signaling by SUR ligands. Insulin
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stimulates various aspects of glucose utilization through the PI-3K pathway
(146). In particular, glucose transport is the rate-limiting process for glycogen

synthesis and lipogenesis (83). The regulation of lipogenesis by SUR ligands
in human adipocytes suggests the possibility that glucose transport in
adipocyte is also subject to calcium-dependent modification. One potential
mechanism for sulfonylureas to stimulate glucose transport is by interacting
with the PI-3K pathway. Accordingly, to elucidate the extrapancreatic
actions of SUR ligands on glucose transport and insulin signaling, we
examined the effects of glibenclamide and diazoxide in cultured 3T3-L1
adipocytes.

Materials and Methods
Materials
Human insulin was purchased from Eli Lily (Indianapolis, IN). [1,23

H] 2-deoxyglucose was purchased from ICN Pharmaceuticals, Inc. (Irvine,

CA) with a specific activity of 30 Ci/mmol and a concentration of 1 mCi/ml.
Monoclonal Anti-phosphotyrosine antibody (clone 4G10) was purchased
from Upstate Biotechnology (Lake Placid, NY). Polyclonal anti-IR and antiIRS-1 antiserum were gifts from Dr. Bentley Cheatham (Joslin Diabetes
Center, Boston, MA). Anti-p85 was purchased from Sigma (Saint Louis,
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Missouri). Protein A-Sepharose was purchased from Pharmacia Biothch
(Peapack, NJ). Assay kit for Akt Serine 473 phosphorylation was purchased
from New England Biolabs, Inc. (Beverly, MA). For adipocyte
differentiation, 1-methyl-3-isobutylxanthine (IBMX) and dexamethasone
were purchased from Sigma (St. Louis, MO).

Cell Culture
3T3-L1 fibroblast cells (CCL 92.1; American Type Culture
Collection, Rockville, MD) were grown in monolayer culture in Dulbecco's
modified Eagle's medium (DMEM, 25 mM glucose) supplemented with
10% (v/v) calf serum and 1% (v/v) antibiotic solution (10,000 units/ml
penicillin and 10 mg/ml streptomycin) in an atmosphere of 7.5% CO2 at 37
°C. Confluent cultures were induced to differentiate into adipocytes by
incubating the cells in 0.5 mM 1-methyl-3-isobutylxanthine, 0.25 mM
dexamethasone and 10 mg/ml insulin as described previously (28). Cells
were used for experiments 7-10 days after initiation of differentiation. At
this time, greater than 90% of the cells were filled with lipid droplets. These
cells showed large increases in glucose uptake and in phosphorylation of
signaling molecules in response to nanomolar concentrations of insulin as
described below.
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Determination of 2-deoxyglucose Uptake
3T3-L1 adipocytes cultured in 12-well plates were incubated in
serum-free DMEM for 2 hours before experimental manipulations. 2Deoxyglucose uptake measurements were carried out as described
previously (106). Briefly, following incubations with KATP channel effectors
as indicated, cell monolayers were washed 3 times with Krebs-Ringer
phosphate (KRP) buffer (140 mM NaCl, 1.25 mM MgSO4, 1.25 mM CaCl2,
4.7 mM KCl, 5 mM sodium phosphate, pH 7.4) and any remaining liquid
was aspirated. Cells were then incubated for 15 minutes in KRP buffer in the
absence or presence of the ion channel effectors and/or insulin. 2deoxyglucose uptake was initiated by the addition of 10 µl 2 mM 2-[1,2-3H]
deoxyglucose to a final concentration of 33 nM 2-[1,2-3H] deoxyglucose at a
specific activity of 30 Ci/mmol. Preliminary studies demonstrated that 2deoxyglucose uptake was linear under these condition. For all the uptake
experiment presented, the reaction was terminated after 5 min by rapidly
washing cells three times with ice-cold phosphate-buffered saline (PBS)
containing 10 mM glucose. Cell associated radioactivity was determined by
lysing the cells with 0.05 N NaOH, followed by liquid scintillation counting.
Total cellular protein was determined by the Bradford method (32). To
correct for radioactivity non-specifically associated with the cells or
26

entrapped in extracellular spaces, non-specific uptake was determined in the
presence of 10µM cytochalasin B (106). This value was subtracted from the
uptake in the absence of cytochlasin to obtain specific glucose transport.

Immunoprecipitation
Following treatments with insulin or KATP channel effectors as
indicated, the cells were lysed in 1 ml of lysis buffer (137 mM NaCl, 20 mM
Tris-HCl pH 7.5, 1 mM MgCl2, 1 mM CaCl2, 100 µM Na3VO4, 2 mM
PMSF, 10% glycerol (v/v), and 1% Nonidet P-40 (v/v)). Cell lysates were
then centrifuged for 5 min at 10,000 X g to remove cell debris and nuclei.
The supernatant fractions were pre-cleared by incubation with Protein ASepharose. Anti-phosphotyrosine antibody (2 µg/ tube) was then added for
overnight incubation with shaking at 4 °C, followed by addition of 30 µl
(10% w/v) of protein A-Sepharose for 1 hour. Following centrifugation, the
pellets were washed three times with lysis buffer, solubilized in 30 µl of 2 X
SDS-PAGE sample buffer, boiled for 5 minutes, and separated by 10 %
SDS-PAGE. Following electrophoretic transfer of the proteins to a
polyvinylidene difluoride (PVDF) membrane, an appropriate dilution of
primary antibody was added to the membrane, followed by appropriate
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secondary antibody conjugated to horseradish peroxidase (1:5000 dilution).
Protein was visualized by the enhanced chemiluminescence method (ICN
Biomedicals, Inc., Costa Mesa, CA).

Image Analysis
Densitometry analysis of autoradiograms was performed by scanning
the films electronically using an UMAX Astra 610S scanner connected to a
PowerMacintosh computer. The resultant images were then analyzed by the
NIH Image (v. 1.59) software that measures the area and mean density
values of the bands of interest after substracting the background.

Statistics
All data are expressed as means ± standard deviation. Statistical
analysis of subgroups was performed by independent sample Student’s t test
with significant differences between means determined at a P-value < 0.05.
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Results
Effects on glucose uptake
Interpretation of the effects of diazoxide and sulfonylureas on glucose
transport is complicated in animal studies. Any effects observed could well
be indirect, caused by alteration in pancreatic release of insulin into the
circulation. In order to isolate the extrapancreatic effects of SUR ligands, we
employed cellular assays using cultured 3T3-L1 adipocytes to assess
possible direct effects of these drugs on glucose transport and insulin
signaling. Under our cell culture conditions, virtually all of the 3T3-L1
fibroblasts differentiated into mature adipocytes that exhibit morphological
and biochemical features of adipocytes in vivo (Figure 2-1).

Under our assay conditions, 3T3-L1 adipocytes exhibit a dosedependent increase in glucose uptake in response to varying concentrations
of insulin stimulation (Fig.2-2). The maximum increase in glucose uptake
was about 4 fold and reached a plateau at an insulin concentration of 30 nM.
In contrast, KRC-7 hepatoma cells, which do not express Glut4 showed
virtually no change in glucose uptake.

29

Previous studies with isolated rat adipocytes have suggested that
sulfonylureas bind to cell membranes and potentiate glucose uptake
maximally after a 24-hour exposure (105, 106). We observed that incubating
3T3-L1 adipocytes with 100 µM glibenclamide for 24 hours causes a
consistent 50% increase in basal glucose uptake and a much more modest
increase in insulin-stimulated glucose uptake (Fig.2-3). The increase by
glibenclamide in the absence of insulin appears to be additive with the effect
of insulin alone. In contrast, diazoxide alone (100 µM) does not affect basal
or insulin-stimulated glucose uptake after 24 hours of incubation with the
adipocytes (Figure 2-3).

Because the effect of glibenclamide on insulin release is very rapid,
we also examined the effect of acute exposure to glibenclamide, i.e. with the
drug present during the 15-minute incubation with insulin. At low
concentrations, there was no effect on basal rates of glucose uptake (Figure
2-4). However, at higher concentrations up to 100 µM, we observed a
significant inhibition of basal glucose uptake (Figure 2-4). In the
experiments presented in Figure 2-3, we did not observe this inhibition of
basal uptake. However, although incubation with glibenclamide was for 24
hours, the drug was not present during the last 15 minutes, the period during
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which cells were incubated with insulin to measure the insulin stimulated
uptake. Therefore, we repeated the experiment and included the drug during
the 15 minutes of incubation with insulin and prior to addition of the
radiolabelled glucose. These experiments demonstrated that with the 24-hour
exposure to the drug, we do observe an increase in basal uptake and that this
is observed regardless of whether the drug is removed from the culture
medium for the final 15 minutes prior to incubation with the radiolabelled
sugar (Figure 2-4).

The results presented in Figure 2-3 demonstrating that the effect of
glibenclamide on basal uptake was additive with insulin stimulated uptake
were obtained by incubating the cells with glibenclamide for 24 hours,
washing the cells to remove the drug, and then incubating an additional 15
minutes with or without insulin. That is, the glibenclamide was not present
during the final 15 minutes of the incubation prior to addition of
radiolabelled sugar. We repeated that experiment measuring the effect of
acute or long-term exposure to glibenclamide on insulin stimulated glucose
uptake and kept the glibenclamide present up to and during the period of
incubation with the labeled deoxyglucose. The 15 min exposure to higher
concentrations of glibenclamide causes an inhibition of insulin-stimulated
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deoxyglucose uptake (Figure 2-5) but does not cause any increase over the
effect of insulin alone. The 24 hr plus 15 min exposure to glibenclamide
causes an inhibition of uptake at higher concentrations but causes an
increase over insulin alone at low concentrations (Figure 2-5).

Diazoxide alone (100 µM) does not affect basal or insulin-stimulated
glucose uptake after 24 hours of incubation with the adipocytes (Fig.2-3).
Given that diazoxide is reported to antagonize the effects of the
sulfonylureas, we evaluated the ability of diazoxide to alter the effects of
glibenclamide on insulin stimulated glucose uptake. The potentiation of
insulin-stimulated glucose uptake by 100 µM glibenclamide is not inhibited
by up to 200 µM of diazoxide after 24 hours incubation (Fig. 2-6). Acute
exposure to glibenclamide in the presence of diazoxide does not prevent the
cells from losing more than 50% of insulin-stimulated glucose uptake (Fig.
2-6). The inability of diazoxide to antagonize the actions of glibenclamide
suggests that the KATP channel does not mediate the potentiation effect of
glibenclamide on glucose uptake. Whether it involves changes in
intracellular calcium in adipocytes remains unsettled.
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Effects on Insulin Signaling
Our evidence suggests that the effect of glibenclamide is independent
of the SUR. The possibility exists that glibenclamide might act through an
insulin-signaling pathway independent of the SUR. Accordingly, we have
investigated the effects of glibenclamide and/or diazoxide treatment on
tyrosine phosphorylation of the insulin receptor (IR) and insulin receptor
substrate-1 (IRS1). The association of p85 with tyrosine-phosphorylated
IRS-1 was also examined as an index for PI-3 kinase activation.

To evaluate whether the immunocomplex assay we planned to use is
capable of detecting varying degrees of tyrosine phosphorylation initiated by
insulin, the tyrosine phosphorylation status of IR and IRS1, as well as the
association of p85 with IRS1, were examined in differentiated 3T3-L1
adipocytes with undifferentiated fibroblasts as a control. Undifferentiated
fibroblasts express little, if any, insulin receptor while mature adipocytes
express a significant quantity. The results (Fig. 2-7A and 2-7B) indicate that
IR and IRS1 are heavily phosphorylated at tyrosine residues after exposure
to 100 nM insulin for 10 minutes, in contrast to a much lower level of
tyrosine phosphorylation in the absence of insulin. This response to insulin
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stimulation is absent in undifferentiated fibroblasts, consistent with the lack
of expression of insulin receptor in these control cells.

As further control experiments, the dynamics of insulin signaling was
examined to show the time-dependent changes in tyrosine phosphorylation
of IR and IRS1 (Fig. 2-8). IR becomes phosphorylated as quickly as 1
minute after 100 nM insulin stimulation and stays heavily phosphorylated
even after 10 minutes. A similarly rapid response of IRS1 is consistent with
its action directly downstream of IR. But after 8 minutes, the IRS1 is getting
dephosphorylated. The decrease in IRS1 phosphorylation is independently
reproducible by monitoring p85 association with IRS1 (Fig. 2-9). The
amount of p85 binding to IRS1 was assessed by immunoprecipitation using
a polyclonal antibody against IRS1. An insulin-stimulated increase of p85
binding to IRS-1 reached maximum after 8 minutes and then attenuated,
consistent with the timing assessment made using the anti-phosphotyrosine
antibody (Fig. 2-8). Therefore, under our assay conditions, the changes
observed in tyrosine phosphorylation status are indicative of insulin
signaling in vivo.
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Because the regulatory effects of sulfonylureas and diazoxide on pancreatic
insulin release are virtually instantaneous and the inhibitory actions seen
with glucose uptake are rapid, we have only examined the acute effects of
sulfonylurea and diazoxide on insulin signaling. Glibenclamide and
diazoxide appeared to have little effect on tyrosine phosphorylation of IR
and IRS1 (a representative experiment is presented in Figure 2-10).
Similarly, glibenclamide and diazoxide caused virtually no change in the
association of p85 (or a SH2 domain–containing molecule) with IRS1
(Figure 2-11).

Discussion
Clinical studies in animal and human subjects of NIDDM have
suggested that diazoxide enhances the insulin sensitivity of adipose tissues
in vivo (3-5). Although the improved glucose tolerance in diazoxide-treated
subjects was attributed to the ameliorated hyperinsulinemia, previous studies
in our laboratory and others have also indicated that the anti-diabetic effects
of diazoxide cannot be adequately explained by its pancreatic action alone
(132, 140). An extrapancreatic effect of diazoxide has been documented in

isolated human adipocyte in terms of reversing the effect of glibenclamide
on lipogenesis (132). Glibenclamide has been shown to increase glucose
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utilization by peripheral tissues in vitro and in vivo (6, 32, 39, 65-67).
Moreover, the pharmacological target of sulfonylureas and diazoxide in
pancreas, SUR1, was recently shown to be present in isolated human
adipocytes (132). Therefore, it is possible that diazoxide antagonizes the
multiple effects of sulfonylureas on glucose utilization in adipocytes through
SUR1. In fact, diazoxide was shown to prevent the stimulation of lipogenic
enzyme activities as well as the inhibition of lipolysis by glibenclamide in
isolated human adipocytes. However, if diazoxide antagonizes the
stimulatory effect of glibenclamide on glucose transport as well, one would
predict it to inhibit glucose transport, which is contrary to the observation
made in clinical studies. To investigate this discrepancy and potential
interactions between diazoxide and insulin signaling in adipocytes, the
present study examined the effects of diazoxide on glucose transport and
insulin signaling in cultured 3T3-L1 adipocytes.
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We have demonstrated that diazoxide has no direct effect on the basal or
insulin-stimulated glucose uptake in 3T3-L1 adipocytes (Figure 2-3). The
lack of response was specific to the diazoxide treatments as insulin was able
to stimulate glucose uptake in a dose-dependent manner (Figure 2-2). The
maximal stimulation by insulin was up to 450% of the basal uptake,
presumably due to the mobilization of the Glut4 by insulin signaling .
Consistent with this assumption, insulin stimulated glucose uptake to a much
lesser extent in the KRC-7 hepatoma cells (Figure 2-2), which do not
express the Glut4 (49, 50), but otherwise respond similarly to insulin in terms
of protein tyrosine phosphorylations (data not shown). To further confirm
the action of diazoxide in the adipocytes, we included in our experiments the
use of glibenclamide whose action on lipogenesis was reversed by diazoxide
(132).

Glibenclamide enhanced the basal glucose uptake after long-term
incubation. The increase in the basal uptake by glibenclamide was additive
to the insulin-stimulated glucose uptake and only seen after a 24-hour
exposure to the drug. Stimulation of glucose transport by sulfonylureas has
been documented by a number of studies (26, 31, 32, 39, 65-67, 105, 106, 123,
139, 142, 144, 148, 164). The potentiation by glibenclamide demonstrated in the
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present study is independent of and additive to the acute stimulation by
insulin, suggesting that glibenclamide activates glucose transport
independently of the insulin signal transduction cascade. In addition, the
lack of acute stimulation by glibenclamide in the present study implies a
mechanism that requires protein synthesis to mediate the direct effect of
glibenclamide.

The long-term incubation required for the potentiation by
sulfonylureas has been described by a number of studies, most of which
attributed the increase in glucose transport to enhanced gene expression and
protein translocation of the glucose transporters (66, 67, 105, 106, 142, 148).
Therefore, glibenclamide may increase glucose uptake by activating the
synthesis of glucose transporters. In support of this possibility and consistent
with our observation, glibenclamide and diazoxide have recently been
shown to modify gene expression of key lipogenic enzymes in isolated
human adipocytes (132, 140).

Alternatively, glibenclamide has been shown to decrease the cytosolic
cAMP levels and protein kinase A (PKA) activity in rodent adipocytes and
muscle cells (106). Together with the insulin signaling pathway, cAMP is the
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major intracellular signal that regulates glucose utilization. Sulfonylureas
have been shown to decrease cytosolic cAMP levels and protein kinase A
(PKA) activities in isolated rat adipocytes (17, 106, 153). The decrease in
cAMP-dependent phosphorylation of Glut4 results in a state of the
transporter protein that is competent for translocation to and/or residence in
the plasma membrane (13, 122). In fact, diminished glucose transport activity
is associated with elevated levels of phosphorylated Glut4 in insulinresistant rat adipocytes (13, 122). There is also some evidence for Ser/Thr
phosphorylation of Glut4 by PKA during induction of insulin resistance (68,
81, 86).

Since insulin mobilizes the Glut4 in an acute manner, we also
examined the acute effect of glibenclamide on glucose transport in order to
differentiate the two possibilities described above. Indeed, when the cells
were exposed to glibenclamide for only 15 minutes, the basal and the
insulin-stimulated glucose uptake were not enhanced by glibenclamide at
low concentrations and even suffered from the presence of glibenclamide in
higher (> 10 mM) concentrations (Figure 2-4 and 2-5). Furthermore, when
the cells were exposed to glibenclamide for 24 hours plus an additional 15
minutes in the presence or absence of insulin, the long-term potentiation by
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glibenclamide and the acute insulin stimulation of glucose uptake were still
clearly visible at low concentrations of glibenclamide (< 10 mM). Therefore,
the acute inhibition of glucose uptake by glibenclamide appears to be dosedependent and mediated by a mechanism not specific to either the basal or
the insulin-stimulated glucose uptake. There has been discussion about
whether the effective concentrations of sulfonylureas in vivo were
significantly higher than the expected ones according to in vitro binding
experiments [25]. It remains unclear whether our observation of the acute
inhibition by glibenclamide indicates a similar mechanism or if the high
concentrations of glibenclamide simply have a detrimental effect on the cell
membrane that is unfavorable to the sugar transport process.

Because glibenclamide acutely inhibited the insulin-stimulated
glucose uptake, we were prompted to ask if glibenclamide modifies the
insulin signaling responsible for mobilizing the Glut4. We observed no
modification of the insulin signaling leading to enhanced mobilization of the
Glut4 after acute exposure to glibenclamide (Figure 2-10). Consistent with
the data on glucose uptake experiments, neither glibenclamide nor diazoxide
enhance or inhibit insulin signaling in 3T3-L1 adipocytes in spite of the
demonstration that they improve glucose tolerance in vivo.
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To our surprise, diazoxide was unable to reverse any of the effects of
glibenclamide under the same experimental conditions (Figure 2-6). The
long-term potentiation of basal uptake by glibenclamide in addition to the
acute insulin stimulation was unaffected in the presence of up to 200 mM
diazoxide (Figure 2-6). Similarly, the short-term inhibitory effect of 100 mM
on acute insulin stimulation of glucose uptake was not reversed by the
presence of up to 200 mM diazoxide (Figure 2-6). The lack of antagonism of
the glibenclamide action by diazoxide suggests that the extrapancreatic
effects of glibenclamide on glucose transport in adipocytes are probably not
mediated by SUR1, the pancreatic sulfonylurea receptor. SUR1 is normally
expressed in the pancreas, while isoforms SUR2A and SUR2B are expressed
in other electrically excitable cells (18, 99). There have been both positive
and negative reports on the presence of high-affinity binding sites for
sulfonylureas on the adipocyte membrane (48, 111). However, the expression
of SUR1 was recently demonstrated in isolated human adipocytes and
suggested to mediate the direct effects of glibenclamide and diazoxide on
lipid metabolism (132). In contrast, our data suggest that SUR1-mediated
direct effects of diazoxide and glibenclamide on glucose transport were
unlikely. Considering that glucose transport is the rate-limiting process for
lipogenesis, it remains unclear what is the reason for this discrepancy.
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CHAPTER III

The Effects of Agouti and Agouti-Related
Polypeptide on Insulin Signaling in 3T3-L1 Adipocytes

Introduction
Agouti was the first obesity gene to be cloned (19). Aberrant
expression of the agouti gene results in late-onset obesity and type II
diabetes (104, 161). Several lines of evidence strongly suggest that the
metabolic anomalies induced by mis-expressed agouti stem from its effects
on the central nervous system (35, 38, 64). The recent discovery of AGRP
(Agouti-related polypeptide), which shares striking similarities with agouti
in structure and in biochemical properties (77, 93, 151), indicates that ectopic
agouti mimics the normal biological actions of AGRP. AGRP is expressed
primarily in the hypothalamus, adrenal medulla, and at low levels in testis,
lung, and kidney (109, 134). Both the agouti and AGRP proteins are highly
specific antagonists for the melanocortin receptor MC4-R. MC4-R is also
expressed mainly in the brain [Gantz, 1993 #711] [Mountjoy, 1994 #712]. Central
administration of synthetic MC4-R antagonists stimulates feeding behavior
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and metabolism (38), indicating a functional role for melanocortin
antagonists in vivo (64). Therefore, the identification of a hypothalamic
melanocortin receptor, MC4-R, together with AGRP as central components
of feeding behavior and metabolism has lent support for a central mechanism
of agouti-induced obesity.

However, a significant number of studies have also suggested that
agouti has additional effects on insulin-sensitive peripheral tissues such as
adipose tissue and the pancreas (24, 71, 79, 155, 156, 163). Based on the
structural similarity between agouti and the invertebrate neurotoxins which
are known to block calcium channels, Zemel et al have proposed that agouti
is able to regulate lipogenesis and insulin release via a calcium-dependent
mechanism (162). In support of the peripheral actions of agouti, Xue et al.
have shown that recombinant agouti protein exhibits potent lipogenic and
antilipolytic effects in human adipocytes via a calcium-dependent
mechanism (71, 79, 155), thereby promoting lipid storage in adipose tissue.
Subsequent data from the same laboratory demonstrated that agouti protein
stimulates calcium signaling and serves as a potent insulin secretagogue in
both a pancreatic ß-cell line and human pancreatic islets (154). Accordingly,
they have proposed that this effect of agouti on insulin release, combined
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with its effect on adipocyte lipid metabolism, may represent an alternative
mechanism for agouti in the development of obesity.

The fundamental similarity between insulin secretion and glucose
transport raise the possibility that if agouti is able to stimulate the exocytosis
of insulin, it may be able to stimulate Glut4 translocation in adipocytes,
another calcium-affected exocytotic event. Since agouti is a paracrine factor
(104), it may directly stimulate glucose transport into adipose tissue, or it

may do that indirectly via increased plasma insulin levels. Furthermore,
although the obesity appears to be caused by agouti's effect on feeding
behavior that is controlled by the hypothalamus (35, 74), the molecular
mechanism which links obesity to peripheral insulin resistance is still not
fully understood. The current understanding of agouti action does not
explain the molecular mechanism by which the increased adiposity causes
insulin resistance. However, it was recently reported that in cultured 3T3-L1
adipocytes, agouti stimulates the transcription of the fatty acid synthase
(FAS) gene that is normally regulated by insulin (24). Insulin stimulates FAS
transcription through a cascade of kinase activity including PI-3 kinase (PI3K) and its downstream effector, Akt or protein kinase B (PKB) (147). This
observation raises the possibility that agouti may interact with insulin
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signaling. Perhaps the induction of FAS activity by agouti involves
activation of the insulin signaling pathway. If so, then this persistent
activation of the pathway by ectopically expressed agouti could lead to
down-regulation (desensitization) of the pathway.

Whether the action of agouti is central or peripheral, the proposed
mechanisms for agouti stimulation of lipogenesis and insulin secretion has
significant implications for our understanding the molecular mechanism
underlying insulin resistance in type II diabetes. We are particularly
interested in the PI-3K pathway because of its essential role in the process of
insulin-stimulated glucose transport and lipogenesis. In order to assess the
potential interaction between agouti protein and insulin signaling, we
examined agouti’s effects on the insulin-stimulated glucose transport and
activation of PI-3K pathway in 3T3-L1 adipocytes.

Materials and Methods
Materials
Partially purified recombinant agouti was a gift from Dr. Naima
Moustaid-Moussa and its preparation has been described elsewhere (24, 93).
Synthetic C-terminal peptide (residues 83-131) of AGRP was purchased
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from Phoenix Pharmaceuticals, Inc. (Phoenix, AZ). The C-terminus of
AGRP has been shown to retain the biological activity of the full-length
protein in vivo and in vitro (124, 160). Reagents and antiserums for 2deoxyglucose uptake and immunoprecipitation experiments have been
described in “Materials and Methods “ of chapter II. For FAS enzyme
activity assay, NADPH, malonyl CoA and acetyl CoA were purchased from
Sigma (St. Louis, MO).

Cell Culture
3T3-L1 fibroblast cells (CCL 92.1; American Type Culture
Collection, Rockville, MD) were grown and induced into differentiated
adipocytes as previously described in “Materials and Methods “ of chapter
II.

Determination of 2-deoxyglucose Uptake
Deoxyglucose uptake measurements were carried out according to
Muller et al. (106) and has been described in “Materials and Methods “ of
chapter II.
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Immunoprecipitation and western blot analysis
Immunoprecipitation with monoclonal anti-phosphotyrosine
antiserum and western blot analysis was performed as previously described
in “Materials and Methods “ of chapter II.

FAS enzyme activity assay
FAS enzyme activity was measured spectrophotometrically in crude
cytosolic extracts of 3T3-L1 adipocytes by monitoring the oxidation rate of
NADPH at 340 nM. The enzyme activity was normalized to per min and per
mg protein as previously described (24, 71).
Statistics
All data are expressed as means ± standard deviation. Statistical
significance was assessed by independent sample Student’s t test. A P-value
< 0.05 was considered significant.

47

Results
Effect of agouti and AGRP on Glucose Transport
As shown in Figure 3-1 and 3-2, 2-deoxyglucose uptake was
measured in 3T3-L1 adipocytes in the presence of increasing concentrations
of agouti protein. Exposure of 3T3-L1 adipocytes to agouti protein
concentrations ranging from 1.45 nM to 745 nM has very little effect on
basal 2-deoxy glucose uptake (Figure 3-2) or on the 100 nM insulinstimulated uptake (Figure 3-1). One hundred nm insulin alone gave a 5-fold
stimulation, the maximal observed response. The lack of response to agouti
protein was further confirmed in another experiment using 3 nM insulin, a
more physiological concentration (Figure 3-2). Because this concentration
does not give maximal induction, it allows for the possibility of additional
effects of agouti that might be manifest as an increase in activity. It also
allows for the possibility that agouti might inhibit the insulin stimulated
glucose uptake in the presence of an insulin concentration closer to
physiological.

Effect of agouti and AGRP on insulin signaling
To assess the potential effects of agouti or AGRP on insulin signaling,
we examined the insulin-stimulated tyrosine phosphorylation of IR and IRS-1
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as well as the activation of Akt/PKB in the presence of 100 nM agouti or
AGRP. As shown in figure 3-3, 100 nM agouti has no detectable effect on
tyrosine phosphorylation of IR. Similarly, tyrosine phosphorylation of IR and
IRS-1 was not affected by 100 nM AGRP (Figure 3-4). Examination of Akt
/PKB activation by insulin also revealed that phosphorylation at Ser473 was
not affected by the presence of 100 nM AGRP (Figure 3-5).

Effect of agouti and AGRP on FAS enzyme activity
Pharmacological studies of murine agouti have concluded that its
mechanism of action is a classical competitive antagonism of melanocortin
receptors (78, 93, 113, 151). In addition, In vitro studies using recombinant
mouse agouti protein have shown that agouti is a potent melanocortin
antagonist (nanomolar range) at MC-R subtypes 1 (KI(app) = 3 ± 1 nM) and
4 (KI(app) = 54 ± 18 nM), a relatively weak antagonist at MC3-R
(KI(app) = 190 ± 74 nM), and a very weak antagonist at MC5-R
(KI(app) = 12,000 ± 340 nM) (78, 93, 151).

As we observed virtually no stimulation or inhibition of glucose
transport by agouti protein at concentrations encompassing its potency to
antagonize MC1-R, MC3-R and MC4-R, one potential explanation that
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could account for the lack of an effect is that our agouti protein was not
biologically active. Seeking to eliminate this possibility, we measured the
effects of agouti and human AGRP on Fatty Acid Synthase (FAS) activity in
3T3-L1 adipocytes. A previous study by Claycombe et al. (24) has
demonstrated that agouti and insulin independently and additively regulate
lipogenesis by inducing FAS activity in 3T3-L1 and primary human
adipocytes. The mechanism of FAS activity induction by insulin and agouti
is through similarly positive regulation of FAS mRNA content.

Consistent with the previously reported value, we observed a 2-3 fold
increase in FAS activity by 100 nM insulin treatment (Figure 3-8). However,
there is no stimulation of FAS activity by agouti or AGRP either in the
absence or presence of insulin. Interestingly, the ability of insulin to
significantly induce FAS activity in 3T3-L1 adipocytes appears to be limited
to the first week after the induction of differentiation. In fact, measurements
of FAS activity using 3T3-L1 adipocytes 10 days into differentiation showed
a much higher basal activity (~ 12 fold) and a 25 % decrease in FAS activity
after a 48-hour exposure to 100 nM insulin (Figure 3-6).
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Discussion
Previous studies have indicated that agouti protein enhances
lipogenesis in vivo and in vitro (24, 71, 79, 155). Of particular interest, the
experiments in vitro using cultured 3T3-L1 adipocytes and isolated human
adipocytes demonstrated that agouti increased the transcription of FAS gene
(24), which is also regulated by insulin through activation of the PI-3K

pathway (147). Therefore, it appeared that agouti may have direct effects on
the activation of PI-3K and subsequently the glucose transport and
lipogenesis. However, in the present study, we demonstrated that in cultured
3T3 –L1 adipocytes, agouti protein has no effects on insulin stimulation of
glucose transport and PI-3K activation.

The lack of response to agouti was observed under the same
experimental conditions where insulin was able to stimulate glucose uptake
to different degrees (Figure 3-1 and 3-2). The response to insulin
stimulation indicates that the glucose transport process was not impaired in
any way and so the absence of effects by agouti is specific to this reagent.
Agouti at various concentrations not only failed to enhance glucose uptake
beyond the maximal induction by insulin, they were also unsuccessful in
stimulating glucose uptake even when the stimulation was submaximal (i.e.,
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with 3 nM insulin). Therefore, agouti protein does not stimulate glucose
uptake independent of insulin or synergistically with insulin. Similarly, the
basal uptake was not affected by incubating with various concentrations of
agouti protein that encompass the effective concentrations documented in
the literature regarding its antagonism at the MC-R’s (78, 93, 113, 151). Thus,
the results on glucose uptake suggest that agouti may stimulate glucose
uptake through an alternative mechanism, or the agouti reagent we used may
be biologically inactive.

In order to confirm the biological activity of our agouti reagent, we
examined its documented effects on the FAS gene expression in the 3T3-L1
adipocytes (24). This experiment also served to assess the possibility that the
effects of agouti may require a longer time frame to manifest. Compared to
the 15 min incubation in the glucose uptake experiment, cells were
incubated with agouti protein for 48 hr as previously described. As an
additional control, we also included in our experiment the C-terminal
peptide derived from the human AGRP. Despite this, no induction of the
FAS enzyme activity by agouti or AGRP was detected, although insulin
produced a 3-fold induction in FAS enzyme activity under certain conditions
(Figure 3-8). Therefore, in contrast to previous studies demonstrating a
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peripheral effect of agouti on lipogenesis, our results suggest that agouti and
AGRP have no effect on the FAS gene expression. Although we cannot
completely exclude the possibility that both agouti and AGRP were
biologically inactive in our experiments, it is unlikely given that the peptide
has been shown to be biological equivalent to the full-length protein in vivo
as well as in vitro (124, 160).

Interestingly, the induction by insulin we observed in the FAS enzyme
assay was present only when adipocytes early into differentiation were used
(Figure 3-8). When cells more than one week into differentiation were used,
the basal activity of FAS enzyme became much higher and the induction by
insulin decreased (Figure 3-7). After 10 days into differentiation, basal FAS
activity rose to a level at least 10 fold higher than that previously reported
and no response to insulin stimulation was detectable (Figure 3-6). The
results suggest that the insulin induction of FAS activity previously reported
may very well arise from the hormone’s ability to promote adipocyte
differentiation. Whether agouti or AGRP enhances lipogenesis through
direct effects on adipocyte differentiation remain unclear at this point, but
our data suggest that regardless of the extent of differentiation, agouti and
AGRP have no effect on FAS enzyme activity
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CHAPTER IV
The Effects of Hyperglycemia on Hepatic
HNF-1α Protein Abundance and Binding Activity

Introduction
Hepatocyte Nuclear factor-1α (HNF-1α) is a homeodomaincontaining transcription factor (23, 45, 108), well studied for its roles in the
development and regulation of liver functions (20). Mice deficient in HNF1α developed phenylketonuria and died from acute wasting in one month
(116). In adult liver, HNF-1α regulates the tissue-specific expression of a

number of genes involved in the synthesis of serum proteins, regulation of
carbohydrate metabolism, and detoxification (22, 27, 53). The liver-specific
expression of these genes is regulated at the level of transcriptional initiation
(22). HNF-lα was first identified as the transcriptional activator interacting

with an essential DNA sequence that confers liver-specific transcription on
the albumin, α-fibrinogen, and α1-antitrypsin promoters (22, 27, 53). HNF-1α
binding sites have since been found in the promoters of more than 30 liverspecific genes (20). In cultured hepatoma cell lines, the expression of HNF1
strictly parallels the differentiated phenotype of the hepatocytes (12, 21, 22,
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85). Dedifferentiated hepatocytes have no detectable HNF-1α transcripts (20)

instead expressing HNF-1β, but selection for reversion to the hepatic
phenotype was accompanied by re-expression of HNF-1α (12, 21). However,
the recent discovery that mutations in the HNF-1α genes are associated with
Maturity-onset Diabetes of the Young (MODY) implies that pancreatic
HNF-1α may have an additional role in the regulation of carbohydrate
metabolism (54, 112, 127).

Although HNF-1α is a transcription factor enriched in liver and
involved in tissue-specific regulation of hepatic genes, it is also expressed in
pancreatic islets, insulinoma cells and other tissues (115). In cultured
insulinoma cells, dominant-negative suppression of HNF-1α activity results
in pronounced decreases in transcription of the insulin gene as well as in the
expression of genes involved in glucose transport (Glut 2) and glucose
metabolism (pyruvate kinase) (152). Dominant mutations in the human HNF1α genes result in MODY3, a monogenic form of NIDDM (159). In clinical
studies, prediabetic patients of MODY exhibit normal insulin sensitivity but
have severe defects in glucose-induced insulin secretion, suggesting that
pancreatic dysfunction is the primary disorder in the disease. Diminished
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insulin storage and exocytosis are consistent not only with MODY3, but also
with MODY1, which is caused by mutations in the HNF-4 genes whose
products regulate the expression of HNF-1α (158). Therefore, diminished
HNF-1α activity in the pancreas is sufficient to initiate the development of
type II diabetes.

Interestingly, diminished HNF-1α activity in the liver of experimental
animals has also been documented in studies of type I diabetes (10, 11).
Albumin transcripts are reduced in type I diabetic livers (10) and albumin
expression in the liver is predominantly controlled by the activity of HNF1α. In fact, only fully differentiated hepatocyte cell lines that express HNF1α at high levels secret albumin at appreciable levels (20). Consistent with
down-regulated albumin transcription, the abundance and DNA-binding
activities of HNF-1α were also decreased in the livers of streptozotocintreated diabetic rats (10). They exhibit hypoinsulinemia and severe
hyperglycemia. Subsequent experiments using vanadate and phlorizin to
normalize the hyperglycemia without changing circulating insulin levels, not
only restored the levels and DNA-binding activities of HNF-1α but also the
albumin mRNA levels (11). Examination of various deletion mutants of the
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albumin promoter suggested that the sequence to which HNF-1α binds
mediates the suppressive effects of hyperglycemia (10). Therefore, the
transactivational activity of hepatic HNF-1α appears subject to regulation by
plasma glucose.

Taken together, the down-regulation of hepatic HNF-1α activity by
hyperglycemia in type I diabetes suggests a mechanism that potentially
mediates the development of type II diabetes through hyperglycemiainduced decreases in pancreatic HNF-1α activity. Preliminary studies in our
laboratory have indicated that hepatic HNF-1α DNA-binding activity is
significantly reduced in the obese Zucker rats (Figure 4-1). This activity is
restored in animals treated with diazoxide. It is possible that the reduction
observed is due to the hyperglycemia observed in these animals, as found in
the liver in type I diabetes. This may well contribute to the alterations in
hepatic glucose metabolism observed in the type II diabetic animal.

In order to confirm our speculation that hyperglycemia results in
diminished hepatic HNF-1α activities and/or protein levels in type II
diabetes, we followed up the preliminary studies performed with the obese
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Zucker rats by examining the amount of HNF-1α protein expressed in the
hepatonuclear extracts from these animals and in cultured Fao rat hepatoma
cells exposed to various concentrations of glucose.

Materials and Methods
Materials
Dulbecco's modified Eagle's medium (DMEM) was from GIBCO,
Grand Island N.Y. [α]-32P-dCTP was from ICN (Irvine, CA). Ironsupplemented bovine serum was obtained from Hy-Clone (Logan, UT).
Pepstatin A, leupeptin, PMSF, and poly dI-dC were purchased from
Boehringer Mannheim (Indianapolis, IN). Aprotinin was purchased from
Sigma (St. Louis, MO). Oligonucleotides were purchased from Oligo etc.
(Wilsonville, OR). The Fao cell lines were obtained from Mary Weiss. AntiHNF-1α antiserums are kind gifts from

Animals procedures
Seven-week-old female Zucker fat (fa/fa) rats and female Zucker lean
(Fa/Fa) rats were used in this study. The animals were maintained as
previously described by Alemzadeh et al (3). Diazoxide (150 mg/kg/day)
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was administered in two doses daily by gavage using Proglycem pediatric
suspension (Baker-Norton Pharmaceuticals, Inc.). The animals in control
group were treated with equivalent volume of placebo suspension twice
daily. Treatments with diazoxide proceeded for a period of 6 weeks. Rat
livers were removed immediately after death, frozen in liquid nitrogen and
stored in -80oC until experiments. The animal procedures were reviewed and
approved by the University of Tennessee Medical Center animal care
committee.

Cell Culture
Fao rat hepatoma cell lines were grown in DMEM containing 10%
iron-supplemented bovine serum in a humidified atmosphere of 10% CO2,
90% air. Cells to be used for experiments were grown to about 70%
confluency and then incubated overnight in serum-free medium. Medium
containing glucose and xylose of different concentrations were then added
and incubations continued for the times indicated in individual experiments.

Nuclear Extract
Nuclear extracts were prepared according to the established protocol
in our laboratory. Unless specified otherwise, each step was performed at
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4oC and in the presence of protease inhibitors (100 µg/ml PMSF, 0.5 µg/ml
leupeptin, 1µg/ml pepstatin A, and 2 µg/ml aprotinin). Briefly, rat liver or
Fao hepatoma cells were homogenized in the homogenization buffer, HB
(10 mM HEPES, pH 7.5, 0.5mM spermidine, 0.15 mM spermine, 5 mM
EDTA, 0.25 mM EGTA, 50 mM NaF and 7 mM 2-mercaptoethanol). The
homogenate was then centrifuged at 7,500 X g for 15 min, and the pellet was
resuspended in 4 ml of solution #2 (1X HB, 0.5 mM sucrose, and 0.05% NP40). After centrifuged at 10,000 X g for 15 min, the resultant pellet was
resuspended in 5 ml of solution #3 (1X HB, 0.35 mM sucrose). The
centrifugation and washing was repeated one more time with 2.5 ml of
solution #3, and the nuclei-containing pellet was resuspended in 4 ml of
solution #4 (1X HB, 10% glycerol, and 50 mM NaCl). Low-salt extraction
was performed for 15 min by mixing on a rocking platform. After
centrifugation at 10,000 X g for 20 min, the remaining pellet was
resuspended in solution #5 (1X HB, 10% glycerol, and 300 mM NaCl). High
salt extraction was performed for 60 min with mixing by agitation followed
by centrifugation at 3,000 X g for 30 min. Solid ammonium sulfate (0.326
g/ml) was then added to the supernatant fraction containing nuclear proteins
and mixed for 30 min by agitation. The mixture was centrifuged at 30,000 X
g for 30 min, and the pellet resuspended in 1 ml of solution #6 (1X HB, 10%
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glycerol, 50 mM NaCl, and 2mM MgCl2). The nuclear extract was then
dialyzed overnight against 300 ml of solution #6. After measuring protein
concentration the nuclear extracts were stored as small aliquots at – 80 oC
until further use.

Electrophoretic mobility shift assay
Two complementary single strands of oligonucleotides containing the
HNF-1α binding site were purchased form Oligo’s etc (Wilsonville, OR),
annealed and [32P]-labeled by the Klenow fill-in reaction for use as a probe:
5' - GATCCGTGGTTAATGATCTACAGTTAT
GCACCAATTACTAGATGTCAATAGATC - 5'

Nuclear extract was incubated together with about 50,000 cpm of the
probe in a reaction mixture containing gel shift buffer (20 mM HEPES, pH
7.9, 40 M KCl, 2 mM MgCl2, 1 mM DTT, and 4% Ficoll), spermidine (2.5
mM), poly(dIdC) (1µg), sonicated salmon sperm DNA (1µg), and pGEM3Z
(Promega) (1µg). After incubation at room temperature for 30 min, 20 µl of
the reaction mixture was resolved by electrophoresis in a 5% nondenaturing
polyacrylamide gel in TBE buffer at 150 V for 2 hr. Where indicated, 1 µl of
anti-HNF-1α antiserum was added to the reaction mixture prior to the
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addition of the probe. After electrophoresis, the gel was exposed to Kodak
XAR-5 film at –80 oC before development.

Results
In order to determine whether a modification of HNF-1α exists in the
liver of type II diabetes, previous studies in our laboratory examined the
promoter-binding activity of liver nuclear extracts prepared from the obese
Zucker rats, an animal model for type II diabetes (Benninghoff, unpublished
data). The promoter-binding activity of liver nuclear extracts was assessed
by the electrophoretic mobility shift assay (EMSA) using a synthetic probe
derived from the target sequence of HNF-1α in the albumin promoter. As
shown in Figure 4-1, DNA binding was decreased more than 80% in the
obese liver nuclear extracts when compared to that of the lean controls.
Furthermore, this decrease is almost fully reversible by diazoxide treatment
in the obese group. In contrast, diazoxide caused a 70% reduction, instead
of an increase, in DNA binding in the liver extracts of lean animals.

We also examined the protein levels of HNF-1α in the liver extracts
of the Zucker rat because the abundance of this transcription factor was
reduced in the type I diabetic animals (11). As determined by western blots
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(Figure 4-2), the protein levels of HNF-1α were modestly higher in the
livers of obese animals than that in the lean controls. Diazoxide treatment
did not significantly affect the abundance of the HNF-1α protein in either
genetic group. Interestingly, the abundance of HNF-1α in liver extracts
could not account for the differences in promoter-binding activity observed
in EMSA assay.

Given that the obese Zucker rats were mildly hyperglycemic, the
decreased binding to the promoter sequence we observed in the EMSA is
consistent with the notion that hyperglycemia suppresses HNF-1α binding
activity. However, our experimental animals were also severely
hyperinsulinemic due to the inherent insulin resistance characteristic of type
II diabetes. Diazoxide blocks insulin secretion and therefore indirectly alters
serum glucose levels as well. Consequently, it is difficult to assess the effect
of hyperglycemia or hyperinsulinemia alone in the obese animals. More
importantly, there was no significant change in the plasma glucose levels in
the diazoxide-treated lean animals (3), indicating that the dramatic reduction
in nuclear extract binding that we observed in EMSA was not caused by
changes in glycemia in the lean animals.
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To confirm that hyperglycemia was indeed the cause of changes in
HNF-1α binding activity in the obese animals, we chose to evaluate the
binding activity and the amount of HNF-1α protein in the Fao rat hepatoma
cell line grown in the presence of different glucose concentrations. The use
of a cultured cell line eliminates the inherent complications in trying to
manipulate glycemia in whole animals. In addition, this cell line has been
demonstrated to reflect the intact liver in terms of albumin expression,
regulation of albumin expression and expression of HNF-1α (20, 22, 70).

When nuclear extracts of Fao cells were examined by EMSA, there
were multiple protein-DNA complexes being detected (Figure 4-3). To
identify the protein-DNA complexes that contain HNF-1α, we utilized
antibodies against HNF-1α to alter the formation of the normal complexes.
In the presence of the HNF-1α antibodies, the two predominant complexes
disappeared and a single band of higher molecular weight and lower
intensity appeared. Thus, these two bands affected by the antibodies are
most likely due to HNF-1α interaction with the ologonucleotide. This
doublet pattern is also consistent with the ability of HNF-1α to dimerize
with different partners and further interact with other nuclear proteins to
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enhance DNA binding. Similar patterns of DNA-protein complexes have
been observed by us and others using cell or liver nuclear extracts (10, 11).

Quantitative densitometric analysis of the two predominant DNAprotein complexes revealed that HNF-1α binding activity was decreased in
Fao cells exposed to 15 and 25 mM glucose (Figure 4-3 and 4-4). This
reduction was minimal after 24 hr exposure but was increased by longer
exposure to high glucose concentrations. Compared to normal (5 mM)
glucose concentration, 15 mM glucose resulted in 20% and 30% reductions
in HNF-1α binding activity after 36 and 48 hr of incubation. Incubation with
25 mM glucose caused a similar reduction, which was not significantly
different from that observed with15 mM glucose. Exposure to glucose for
longer than 48 hr involved replacing the culture medium and, therefore,
replenishing the glucose levels. As a result, HNF-1α binding activity
showed a more variable response after 48 hr (data not shown).

The decrease of HNF-1α binding activity caused by high glucose
concentrations in Fao cells raised a number of questions about the molecular
mechanism(s) mediating this response. One potential mechanism for glucose
to decrease HNF-1α activity is through down-regulation of HNF-4 activity.
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HNF-4 is the transcription factor largely responsible for tissue-specific
expression of HNF-1α (20). Mutations in the HNF-4 gene result in MODY1,
presumably due to detrimental effects on HNF-1α expression and
consequently diminished insulin gene expression in the pancreas.
Furthermore, the glucose-responsive expression of L-pyruvate kinase (LPK) in the pancreas is partially mediated by HNF-4 (34, 51, 92, 100, 101,
110, 121, 157), indicating a precedent for glucose to regulate HNF-4
activity. Therefore, we also examined, by EMSA, the effect of high glucose
concentration on HNF-4 binding activity in Fao cells. However, the
abundance of HNF-4 is much lower than that of HNF-1α, making it difficult
to determine whether there is specific reduction due to the high glucose
concentrations (data not shown).

Other aspects regarding HNF-1α activity we tried to address were the
effects of high glucose concentration on the protein levels of HNF-1α and
albumin. Western blots of nuclear extracts prepared from Fao cells suggest
that there is no significant change in HNF-1α protein levels due to exposure
to different concentrations of glucose (Figure 4-5). Similarly, western blots
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of postnuclear supernatants from Fao cells indicate there is no significant
change in albumin protein levels either (Figure 4-5).

Discussion
We have demonstrated that HNF-1α binding activity was sharply
reduced in the hepatonuclear extracts of type II diabetic animals (Figure 41). This reduction is consistent with the previous reports that hyperglycemia
suppresses the hepatic HNF-1α activity in animals with type I diabetes (10,
11). Because the suppressed HNF-1 activity can be rescued by restoring

euglycemia in type I diabetic rats without altering insulin secretion, it was
suggested that hyperglycemia alone induced an insulin-resistant state that
resulted in lower HNF-1α activity and decreased albumin expression.
However, it is unclear in the previous studies that whether this
hyperglycemia-induced insulin resistance can be compensated by high levels
of insulin as in type II diabetes.

Both hyperinsulinemia and hyperglycemia were observed in obese
Zucker rats (149), reflecting the conditions in type II diabetes. In order to
assess the direct effect of hyperinsulinemia, the experimental animals were
given diazoxide (3, 5). When hyperinsulinemia was ameliorated by
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diazoxide, euglycemia was restored in the obese Zucker rats and the HNF1α binding activity was rescued and returned to control levels. For
comparison, the postabsorptive plasma insulin level in the diazoxide-treated
obese animals was 62% lower than that of the obese control, nonetheless still
3-4 times higher than the lean control (5). In contrast, the post-absorptive
plasma glucose levels of the diazoxide-treated obese animals were fully
returned to the levels of lean controls, as was the HNF-1 binding activity.
Therefore, it appears that the hepatic HNF-1α activity is more closely
correlated with the plasma glucose level than with the plasma insulin levels
in the obese animals.

While attenuating insulin secretion in both genetic strains (5),
diazoxide treatment resulted in opposite regulation of HNF-1α binding
activity in the obese and in the lean animals. In lean animals, diazoxide
caused a 70% loss in HNF-1α binding activity despite no change in the
plasma glucose levels. This glycemia-independent reduction is probably due
to the subnormal insulin levels that failed to sustain the full HNF-1α activity
and albumin expression (10, 11). The obese animals treated with diazoxide
did not suffer this reduction since they still have plasma insulin levels
several times higher than normal. Therefore, our data suggests that
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hyperinsulinemia did not affect the HNF-1α binding activity directly in the
type II diabetic rats.

Furthermore, we have shown that the decrease in hepatic HNF-1α
binding activity was not associated with a concomitant reduction in the
abundance of this transcription factor in the livers of obese Zucker rats.
Western blots of hepatonuclear extracts revealed that the obese animals, in
spite of having lower HNF-1α activity, in fact have slightly higher HNF-1
protein levels than their lean littermates (Figure 4-2). In addition, diazoxide
had no significant effect on HNF-1α protein levels in either the lean or
obese animals. Therefore, the changes in HNF-1α binding activity caused by
obesity or the diazoxide treatment cannot be explained by the changes in the
HNF-1α protein levels. In comparison, previous studies on type I diabetic
rats have shown that the DNA-binding activity and protein levels of HNF1α were both reduced in the diabetic animals (10, 11). It is unclear whether
this discrepancy between our observations and others is due to the extent of
hyperglycemia or the presence of hyperinsulinemia. Compared to the obese
Zucker rats, the streptozotocin-rendered diabetic rats have plasma glucose
levels twice as high and much lower insulin levels (10, 11). If
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hyperglycemia indeed down-regulated the protein levels of HNF-1α, the
glycemia condition in the type II diabetic animals may be too mild to elicit a
significant reduction in the presence of strong mitogenic response to the
hyperinsulinemia. Alternatively, post-translational modification of HNF-1α
may be involved in mediating the effects of hyperglycemia and diazoxide
treatment. A second protein which interacts with HNF-1α and mediates its
binding to the target sequence may also be subject to the regulation by
changes in glycemia, as suggested by the doublet binding pattern in EMSA
(Figure 4-3 and 4-4).

To isolate the effects of hyperglycemia on HNF-1α activity in vitro,
we evaluated the expression of HNF-1α activity in Fao rat hepatoma cells
cultured in different concentrations of glucose. The results of these studies
confirm that high concentrations of glucose alone suppress HNF-1α activity
in Fao rat hepatoma cells. The reduction in HNF-1α binding activity was not
due to increased osmotic stress as reported previously because the medium
with the lower glucose concentrations were supplemented with appropriate
concentration of xylose to equalize the osmolarity in the culture medium.
Compared to the animal studies of type I and type II diabetes, the extent of
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reduction in HNF-1α activity we observed in Fao cells was far more modest.
One possible explanation for this discrepancy is that insulin is required to
maintain the full activity of HNF-1α. Even the type I diabetic rats rendered
insulin deficient by streptozotocin still have one-third the normal insulin
levels (10, 11). Consequently, when the hyperglycemia was ameliorated by
vanadate or phlorizin, the residual insulin level was still enough to sustain
the full return of HNF-1α activity. In contrast, our Fao cells were depleted
of insulin while incubating with different concentrations of glucose.
Nonetheless, the difference in HNF-1α activity between 5 mM glucose and
higher concentrations suggests that HNF-1α activity was indeed affected by
the high glucose concentration. Exposure to 25 mM glucose resulted in a
reduction similar in extent to that caused by 15 mM glucose probably due to
the fact that, in the absence of insulin, there was not much HNF-1α activity
for further reduction.

To address the potential mechanisms accounting for the reduction in
HNF-1α activity, we examined the upstream effector and downstream target
gene of HNF-1 activity. HNF-4 has been shown to mediate the up-regulation
of L-PK by glucose (92). Based on the observation, one would expect that
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high glucose concentrations would increase HNF-4 activity and,
consequently, HNF-1α activity. In contrast, we observed a significant
reduction in HNF-4 activity regardless of the glucose concentration. This
glucose-independent reduction probably is due to, again, the absence of
insulin.

On the other hand, albumin transcription has been shown to be
independent of glucose concentration in the absence of insulin (33). In the
presence of insulin, glucose increases the stability of albumin mRNA. Our
results with albumin protein levels suggest that the albumin message levels
were not affected by the reduction in HNF-1α activity without insulin. Most
likely, the half-life of the albumin protein was too long to demonstrate
significant reduction during the course of our experiments.
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CHAPTER V

Conclusions and Future Directions
Research into the development of type II diabetes and its related
syndromes is crucial for improving the treatments for this disease. Previous
studies elucidating the metabolic staging of type II diabetes have led to
significant advances in the regimen of treatment (127). In addition, novel
therapeutic agents such as thiazolidinediones (TZDs) have provided new
options for treatment (129). However, it remains unclear whether the current
therapeutic approaches truly target the underlying metabolic defects of type
II diabetes.

In the present study, we have taken several experimental approaches
to better understand the molecular mechanisms underlying the insulin
resistance in type II diabetes. First, we examined the direct effects of two
anti-diabetic drugs in cultured adipocytes to gain insight into the molecular
processes that mediate their therapeutic effects. Second, we attempted to
reconstruct the state of insulin resistance in vitro with agouti protein and its
analogue peptide. Last, we examined the effects of high glucose
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concentration on hepatic HNF-1α activity because diminished HNF-1α
activity has been linked to both type I and type II diabetes (10, 11, 159).

These approaches were carried out in cultured cell lines in order to
isolate the molecular components directly affected without the complications
of secondary effects resulting from interacting tissues in studies using whole
animals. The results, in parts, address questions about the insulin resistance
in type II diabetes. Taken together, they outlline the complex interactions
among multiple tissues that lead to the development of type II diabetes.

Extrapancreatic Effects of SUR Ligands
Sulfonylureas are the most widely used hypoglycemic drugs to
stimulate insulin secretion in patients with type II diabetes (127). Our results
demonstrate that glibenclamide, a sulfonylurea, has extrapancreatic effects
on glucose transport in cultured 3T3-L1 adipocytes. The enhancement of
glucose uptake after long-term exposure is independent of insulin’s acute
action, consistent with our observations that SUR ligands have no effect on
the insulin signaling events leading to PI-3K activation. Furthermore, acute
inhibition of glucose uptake by glibenclamide occurs only at concentrations
approaching the limit of solubilization, suggesting that nonspecific damages
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to the membrane temporarily impair the transport process and that long-term
exposure is necessary for the enhancement of glucose uptake.

The molecular mechanism mediates the stimulatory effects of
glibenclamide on glucose utilization is still controversial (106, 132). Our
results indicate that its effects on glucose transport are not sensitive to the
antagonism by diazoxide. The lack of antagonism and the fact that diazoxide
alone has no effect on glucose transport argue against a calcium-dependent
mechanism mediated by SUR1 in the human adipocytes (132). Instead, our
observation is consistent with a cAMP-dependent mechanism previously
demonstrated in cultured 3T3 adipocyte (106). Future experiments in
different species that examine the effects of variety of sulfonylureas and
their sensitivity to diazoxide antagonism in terms of glucose transport will
likely provide more insight into this discrepancy. Alternatively, a potential
explanation may reside in the recent discovery that adipocytes derived from
different fat depots in vivo exhibit differential sensitivity toward insulin
action (74, 136).
Although sulfonylureas are effective in terms of stimulating insulin
secretion, they have significant side effects, which include some
cardiovascular liabilities associated with hyperinsulinemia, and might
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accelerate the progression of the disease by exhausting the pancreatic β-cells
(127). The results presented here suggest that treatments with sulfonylureas

in patients who have lost the ability to secrete insulin may retain the
beneficiary effect of the drugs without the caveat of enhanced lipogenesis.

Agouti /AGRP Effects on Glucose Transport and Insulin Signaling
Our results suggest that agouti or AGRP does not affect glucose
transport in cultured 3T3-L1 adipocytes. In addition, neither agouti nor
AGRP has any effect on the insulin-stimulated tyrosine phosphorylation of
IR, IRS-1 or the activation of the PI-3K pathway. These observations are
consistent with the previous study that overexpressed agouti in an adipocytespecific manner (104, 107). The resultant transgenic animals did not exhibit
the yellow mouse obesity syndromes unless given daily insulin injections
(107). Therefore, insulin resistance in the agouti mouse most likely requires

the interactions of peripheral tissues and perhaps the central nervous system
as well.
The recent discovery of novel signaling molecules and pathways
provides potential mechanism for agouti to elicit such interactions. For
example, resistin was identified as the adipocyte-derived factor whose
expression and secretion is up-regulated during adipocyte differentiation but
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is down-regulated by TZDs (141). TZDs are a class of anti-diabetic drugs
which enhance target-tissue sensitivity to insulin in vivo(129). Resistin serum
levels are markedly elevated in diet-induced obesity as well as genetic
models of obesity and insulin resistance. Administration of recombinant
resistin to mice and cultured adipocytes decreased insulin sensitivity.
Neutralization with anti-resistin IgG reversed the obesity-induced insulin
resistance by potentiating the insulin stimulation of glucose uptake.
Therefore, the effects of agouti on the pancreas or central nervous system
may serve to regulate the expression of resistin which in turn functions as a
signal to decrease insulin-stimulated glucose uptake through an autocrine or
paracrine mechanism.

HNF-1α Activity in Type II Diabetes
Our results strongly suggest that the hepatic HNF-1α activity is
affected by the hyperglycemia in type II diabetes. Although the suppression
of HNF-1α activity did not result in changes in the abundance of albumin
proteins, the decreased transactivation by HNF-1α could elicit different
responses in the expression of other target genes. Of particular interest is the
expression of insulin gene in the pancreas. Because HNF-1α is also
expressed in the pancreas and responsible for the activation of insulin gene
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transcription (20, 145), our observations about the hepatic HNF-1α activity
indicate a potential mechanism for the hyperglycemia to cause defective
insulin secretion in the type II diabetes. To further investigate this
possibility, we propose the following future experiments to address the
various aspects of glucose regulation of HNF-1α activity in the type II
diabetes:

1) To confirm that hyperglycemia could results in decreased HNF-1α
activity in the pancreas of type II diabetic animals, we will examine HNF-1α
mRNA/protein levels and DNA binding activity in β-cells isolated from the
pancreas of obese Zucker rats. We expect the results to be positive, in
consistence with our observation on the liver. Furthermore, the results in
HNF-1α message/protein abundance will provide additional clues as to the
mechanism HNF-1α is modified in response to hyperglycemia.

2) To establish the direct effect(s) of hyperglycemia, we will examine,
in hepatoma and/or insulinoma cell lines, the effects of glucose on HNF1α regulated gene expression in the presence of various concentrations of
insulin. Specifically, we will focus on the transcription of pyruvate kinase
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and insulin genes initially. Both genes are regulated by glucose and by HNF1α (14, 28, 34, 42, 73, 91, 94, 130), indicating that HNF-1α potentially
mediating the effect of glucose. It will be interesting to see how their
promoter activities respond to different combination of glucose and insulin
levels, especially compared to that of the albumin promoter. By assessing
the promoter activity through a reporter gene construct, we hope to eliminate
the interference from the long half-life of mRNA or protein. Alternatively,
we will also attempt long-term exposure of the cells to high glucose, to
simulate more closely the conditions and effects in vivo. Needless to say,
any changes in target gene expression will be correlated with HNF-1α
binding activity determined in the same conditions.

3) For potential post-translational modifications of HNF-1α suggested
by our present results, we will follow up on the gene identified by the aforementioned experiments that are affected by hyperglycemia. Mutation or
deletion study of the promoter will be done to see whether additional DNA
sequence other than the HNF-1α binding site is required for glucose
regulation. If no additional protein factor is implicated, expression of mutant
HNF-1α will be attempted to identify the region that interacts with other
protein factor to facilitate binding to DNA and confers the sensitivity to
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glucose. Alternatively, we will investigate the possibility that HNF-1α is
regulated by AMP-activated protein kinase (AMPK) whose activity is
reduced by elevated glucose concentration (30, 126). This prospect is
supported by the fact that glucose regulation of L-PK in pancreas is
mediated by AMPK (30, 44, 89, 126), although it remains to be seen that
whether HNF-1 is required for this response. We will seek to confirm the
involvement of HNF-1α by expression of dominant-negative HNF-1α
mutants in addition to microinjection of antibodies to the AMPK.
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Figure 1-1. Metabolic staging of type II diabetes. Interactions among
genetic background, aging, and obesity initiate the peripheral insulin
resistance in type II diabetes, followed by pancreatic β-cell dysfunction.
Seconday metabolic changes, including increased fatty acid production and
compensatory hyperinsulinemia, exacerbates insulin resistance in muscle
and liver. The progressive loss of insulin sensitivity eventually results in the
failure of insulin secretion, perhaps mediated by hyperglycemia. As insulin
secretion can no longer compensate for the insulin resistance, impaired
glucose tolerance ensues, leading to full manifestation of diabetes.
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Figure 1-2. The structures and pancreatic actions of Glibenclamide and
Diazoxide. Sulfonylureas such as Glibenclamid (Top structure) bind and
block the pacreactic KATP channels which set the resting membrane potential
of β-cells, leading to membrane depolarization and the opening of voltagegated calcium channels (VDCC). The resultant influx of intracellular
calcium triggers the exocytosis of insulin. Diazoxide (bottom structure)
antagonizes the effect of sulfonyurea by opeening the KATP channels.
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Figure 1-3. Pleiotropic actions of Insulin Signaling. Most metabolic
responses of insulin, including stimulation of glucose transport, are mediated
by the PI-3K pathway. Specific tyrosine phosphorylation of IRS-1 triggered
by insulin binding to its receptors recruit the SH2-domain-containing p85
subunit of PI-3K to the vicinity of plasma membrane. The lipid kinase
activity of PI-3K generates IP3 that activates downstream serine/threonine
kinases which in turn elicits specific metabolic responses such as glycogen
synthesis and lipogenesis. But the specific signal leading to increased
glucose transport is still unknown.
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Figure 1-4. Insulin-stimulated glucose transport. Insulin increases
glucose transport by stimulating the exocytosis of glut4-containing vesicles
from their intracellular sites of sequestration to the plasma membrane. Glut4
is only expressed in skeletal muscle and adipose tissue, tissues that exhibit
insulin-stimulated glucose transport.
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Figure 1-5. Activation of Akt/PKB by Insulin signaling. Phosphorylation
at both Thr308 and Ser473 is essential to the activation of Akt/PKB. Insulin
activates PI-3K, which generates IP3 that binds to the pleckstrin homology
domain of Akt/PKB and recruits it to the membrane where it can be
phosphorylated by PDK1. This lipid binding also results in structural
changes that expose the Thr308 and Ser473 to phosphorylation. Although
Thr308 is known to be phosphorylated by PDK1, the kinase that
phosphorylates Ser473 is still unknown.
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Figure 1-6. Mechanism for the central action of agouti or AGRP.
Ectopic expression of agouti in the hypothalamus mimics the natural action
of AGRP. AGRP antagonizes the effects of α-MSH on the centrally
expressed MC3R and MC4R, leading to increased feeding behavior and
decreased metabolism.
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A.

B.

Figure 1-7. Sequence alignment of murine agouti protein and AGRP. A,
Agouti and AGRP show 25% identity in amino acid sequence, but the Cterminals of the two proteins exhibits much higher identity. The C-terminal
peptide (amino acids 81-131) of AGRP is fully functional as the full length
AGRP in terms of antagonizing α-MSH action at the MC4R. B, the spatial
arrangement of 10 Cys residues in the C-terminals of agouti and AGRP is
similar to that in the invertebrate neurotoxin (GVIA), which acts on the
calcium channels.
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Figure 2-1. Morphology of 3T3-L1 adipocytes during different stages of
differentiation. Panel A, Undifferentiated preadipocytes adopt an irregular
shape in culture. Panel B, Morphology of KRC7 rat hepatoma cells
presented for comparison. Panel C, 4 days after the induction of
differentiation, differentiated 3T3-L1 adipocytes adopt a unicentric
morphology and begin to accumulate lipid droplets. Panel D, 14 days after
induction of differentiation, most 3T3-L1 adipocytes becomes filled with
lipid droplets.
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Figure 2-2. 2-deoxyglucose uptake into 3T3-L1 adipocytes and KRC7
hepatoma cells. 2-deoxyglucose transport into 3T3-L1 adipocytes (solid
bars) and KRC-7 hepatoma cells (hatched bars) was assayed following a 15minute exposure to the indicated concentrations of insulin. The cellassociated 3H-radioactivity measured was corrected for non-specific binding
(incubation in the presence of 10 µM cytochalasin B) and normalized to the
amount of total cellular proteins. The basal uptake of 3T3-L1 adipocytes was
set at 100%. Each point represents the mean (+ SD) of at least four
independent measurements.
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Figure 2-3. Effect of SUR ligands on glucose transport in 3T3-L1
adipocytes. 3T3-L1 adipocytes were incubated in serum-free medium with
the vehicle (0.1% v/v DMSO, the solvent in which the drugs are dissolved),
100 µM glibenclamide, or 100 µM diazoxide for 24 hours. Cells were then
washed to remove the drugs. Cell-associated 3H-radioactivity was measured
in the Krebs-Ringer-phosphate buffer after another 15 minutes incubation
with (solid bar) or without (hatched bar) 100 nM insulin. The results were
corrected for non-specific binding and normalized to the total amount of
cellular proteins.
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Figure 2-4. The acute and long-term effects of glibenclamide on basal
glucose transport into 3T3-L1 adipocytes. 3T3-L1 adipocytes were
incubated with vehicle or the indicated concentration of glibenclamide for
24 hr in serum-free medium before assayed for 2-deoxyglucose uptake. The
cell-associated 3H-radioactivity was measured after another 15 min
incubation with glibenclamide in the Krebs-Ringer-phosphate buffer.
Results were corrected for non-specific binding and normalized to the
amount of total cellular proteins. Each point represents the mean (+SD) of
at least four independent measurements.
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Figure 2-5. The acute and long-term effects of Glibenclamide on insulin
stimulated glucose uptake. 3T3-L1 adipocytes were incubated in serumfree medium with the vehicle (DMSO) or glibenclamide at the indicated
concentrations for 24 hours prior to the 2-deoxyglucose uptake
measurements. Cell-associated 3H-radioactivity was measured in the KrebsRinger-phosphate buffer after another 15 minutes incubation with
glibenclamide at various concentrations and 100 nM insulin. The results
were corrected for non-specific binding and normalized to the total amount
of cellular proteins.
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Figure 2-6. Diazoxide does not antagonize the effect of acute or longterm exposure to glibenclamide on insulin-stimulated glucose transport
in 3T3-L1 adipocyte. 3T3-L1 adipocytes were incubated with 100 µM
glibenclamide and indicated concentrations of diazoxide in serum-free
medium for 24 hr. Prior to the 2-deoxyglucose uptake measurements, cells
were stimulated with 100 nM insulin for 15 min in the absence of the drugs
(24 hr) or in the presence of the drugs (24 hr/ 15 min). Each point represents
the mean ( + SD ) of at least four independent measurements.
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Figure 2-7. Insulin-stimulated tyrosine phosphorylation of IR and IRS1 in 3T3-L1 fibroblasts and adipocytes. 3T3-L1 fibroblasts (- diff.) and
adipocytes (+ diff.) were incubated with or without 100 nM insulin for 10
minutes. Cells were harvested and subjected to immunoprecipitation (IP)
with monoclonal anti-phosphotyrosine (anti-PY) antibodies as described in
Material and Methods. Immune complexes derived from an equal amount of
cell extract protein were resolved by SDS-PAGE and transferred to a PVDF
membrane as described in Material and Methods. Panel A, The membrane
was probed with anti-IR to detect the intracellular β-subunit of IR in the
immunocomplex. Panel B, The membrane was probed with anti- IRS-1 to
detect the IR receptor substrate in the immunocomplex.
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Figure 2-8. Time-course of insulin-stimulated tyrosine phosphorylation
on IR and IRS-1. 3T3-L1 adipocytes were serum-starved overnight before
incubation with 100 nM insulin for the indicated period of time. Cells were
then harvested and subjected to immunoprecipitation (IP) with monoclonal
anti-phosphotyrosine (anti-PY) antibodies as described under “Materials and
Methods”. Western blots were perfomed to detect the phosphotyrosinecontaining IR and IRS-1 in the immunocomplexes (upper and middle panels,
respectively). In the lower panel, equal amounts of cell extract protein were
assessed by western blot to demonstrate the amount of IRS-1 in the cell
extract before immunoprecipitation.
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Figure 2-9. Time-course of insulin-induced p85 association with IRS-1.
3T3-L1 adipocytes were serum-starved overnight before incubation with 100
nM insulin for the indicated period of time. Cells were then harvested and
subjected to immunoprecipitation (IP) with anti-IRS-1 antiserum as
described under “Materials and Methods”. The immunocomplexes derived
from equal amounts of cell extract protein were resolved by SDS-PAGE and
the p85 subunits of PI-3K were detected by western blots as described in the
“Materials and Methods”. In the lower panel, a duplicate western blot of the
immunocomplexes probed with anti-IRS-1 antibody demonstrates that there
are similar amounts of IRS-1 in the immunocomplexes.
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Figure 2-10. Glibenclamide and diazoxide have no effect on insulinstimulated tyrosine phosphorylations on IR and IRS-1. 3T3-L1
adipocytes were treated with vehicle or 100 µM glibemclamide, or 100 µM
diazoxide, or both SUR ligands for 24 hours in the serum-free medium.
Cells were incubated for an additional 10 minutes with or without 100 nM
insulin. Cells were harvested and equal amounts of cell extract protein were
subjected to immunoprecipitation with monoclonal anti-phosphotyrosine
(anti-PY) antibodies, followed by western blots (WB) to detect the
phosphtyrosine-containing IR (left) or IRS-1 (right).
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Figure 2-11. The effects of glibenclamide and diazoxide on the insulinstimulated p85 association with IRS-1. 3T3-L1 adipocytes were incubated
with 100 nM insulin for 10 minutes in the presence of vehicle or 100 µM
glibemclamide, or 100 µM diazoxide, or both SUR ligands. Cells were
harvested and equal amounts of cell extract protein were subjected to
immunoprecipitation with anti-IRS-1 antiserum, followed by western blots
(WB) to detect the p85 subunits of PI-3K that were associated with the IRS1.
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Figure 3-1. The effect of agouti on insulin-stimulated 2-deoxyglucose
uptake in 3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated with 100
nM insulin for 10 min in the presence of various concentrations of agouti
protein as indicated above. 2-deoxyglucose uptake was measured and
expressed as fold induction over basal uptake. Each treatment represents the
average of triplicates (+/- SD) and the experiment was repeated twice.
Statistical significance was determined by Student’s t-test at a confidence
level of P < 0.05.
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Figure 3-2. Agouti was unable to increase 2-deoxyglucose uptake
beyond the submaximal stimulated uptake by 3 nM insulin. 3T3-L1
adipocytes were incubated with or without 3 nM insulin for 10 min in the
presence of various concentrations of agouti protein as indicated in the
figure above. 2-deoxyglucose uptake was measured and expressed as fold
induction over basal uptake. Each treatment represents the average of
triplicates (+/- SD) and the experiment was repeated twice. Statistical
significance was determined by Student’s t-test at a confidence level of P <
0.05. * (P < 0.05).
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Figure 3-3. Agouti has no effect on the insulin-stimulated tyrosine
phosphorylation of IR. 3T3-L1 adipocytes were serum-starved overnight
and incubated with 100 nM insulin for 10 min in the presence or absence of
100 nM agouti protein. Cells were harvested and equal amounts of cell
extract protein were subjected to immunoprecipitation (IP) with monoclonal
anti-phosphotyrosine (anti-PY) antibodies as described in “Materials and
Methods”. Immunocomplexes were resolved by SDS-PAGE and transferred
to a PVDF membrane and probed with polyclonal anti-IR antiserum. The
detected IR represents the phosphotyrosine-containing IR.

129

- + - + - + - +
- - + + + + + +

AGRP
Insulin

WB: IR
IP: anti-PY
WB: IRS-1
IP: anti-PY

Figure 3-4. AGRP has no effect on the insulin-stimulated tyrosine
phosphorylation of IR and IRS-1. 3T3-L1 adipocytes were serum-starved
overnight and incubated with or without 100 nM insulin for 10 min in the
presence or absence of 100 nM AGRP. Cells were harvested and equal
amounts of cell extract proteins were subjected to immunoprecipitation (IP)
with monoclonal anti-phosphotyrosine (anti-PY) antibodies as described in
“Materials and Methods”. Immunocomplexes were resolved by SDS-PAGE
and transferred to a PVDF membrane and probed with polyclonal anti-IR
(top) or anti-IRS-1 (bottom) antiserum. The detected IR and IRS-1
represents the phosphotyrosine-containing IR and IRS-1.
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Figure 3-5. Agouti has no effect on the insulin-stimulated activation of
Akt/PKB. 3T3-L1 adipocytes were serum-starved overnight and incubated
with or without 100 nM insulin for 10 min in the presence or absence of 100
nM AGRP. Cells were harvested and equal amounts of cell extract proteins
were resolved by SDS-PAGE and transferred to a PVDF membrane and
probed with monoclonal antibodies specific for the Akt/PKB phosphorylated
at Ser473 (top) or polyclonal anti-Akt/PKB antiserum (bottom).
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Figure 3-6. The effects of AGRP and insulin on fatty acide synthase
(FAS) activity in 3T3-L1 adipocytes (Day 10). 3T3-L1 adipocytes were
maintained in culture until 10 days after the induction of differentiation.
Cells were then deprived of serum overnight and incubated with or without
100 nM insulin in the presence or absence of 100 nM AGRP for 24 hrs (light
colors) or 48 hrs (heavy colors). FAS enzyme activity was assayed as
described in “Materials and Methods”, and data are expressed as mean
(+SD). The figure is representative of two independent experiments, with a
minimum of triplicates for each treatment. a,b P < 0.05, groups with different
symbols are statistically different from each other.
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Figure 3-7. The effects of agouti and insulin on fatty acid synthase
(FAS) activity in 3T3-L1 adipocytes (Day 8). 3T3-L1 adipocytes were
maintained in culture for 8 days after the induction of differentiation. Cells
were then deprived of serum overnight and incubated with or without 100
nM insulin in the presence or absence of 100 nM agouti (yellow) for 48 hrs.
FAS enzyme activity were assayed as described in “Materials and Methods”,
and data were expressed as mean (+ SD). The figure is representative of two
independent experiments, with a minimum of triplicates for each treatment.
Groups with different symbols are statistically different from each other. a,b
P < 0.01, b,c P < 0.05, 0.05 < a,c P < 0.1.
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Figure 3-8. The effects of AGRP and insulin on fatty acide synthase
(FAS) activity in 3T3-L1 adipocytes (Day 6). 3T3-L1 adipocytes were
maintined in culture until 6 days after the induction of differentiation. Cells
were then deprived of serum overnight and incubated with or without 100
nM insulin in the presence or absence of 100 nM AGRP (yellow) for 48 hrs.
FAS enzyme activity was assayed as described in “Materials and Methods”,
and data were expressed as mean (+ SD). The result is representative of two
independent experiments, with a minimum of triplicates for each treatment.
a,b

P < 0.05, groups with different symbols are statistically different from

each other.
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Figure 3-9. The relationship between adipocyte differentiation and
insulin induction of FAS activity. The basal and insulin-stimulated FAS
activities in 3T3-L1 adipocytes presented in Figures 3-6, 3-7 and 3-8 were
plotted against the length of time that cells stayed in culture after the
induction of differentiation. Insert, fold induction by insulin was calculated
and plotted against the length of time that cells stayed in culture after the
induction of differentiation.
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Figure 4-1. HNF-1 binding activity was sharply reduced in the
hepatonuclear extracts of Obese Zucker rats. Top, a representative
autoradiogram of electrophoretic mobility shift assays (EMSA) obtained
with nuclear extract protein prepared from livers of lean (LN) and obese
(OB) Zucker rats treated or untreated with diazoxide (DZ). Bottom,
densitometry analysis of the autoradiogram shown above. Preparation of
nuclear extracts, EMSA, and densitometry analysis were performed as
describes in “Materials and Methods”.
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Figure 4-2. HNF-1 protein levels in livers of lean and obese Zucker rats.
Levels of HNF-1 proteins in the heptonuclear extracts prepared from the
lean and obese animals were compared by western blot analysis using antiHNF-1 antiserum. Top, equal amounts of nuclear extracts from four lean and
four obese animals were resolved by SDS-PAGE, transferred to a PVDF
membrane and probed with anti-HNF-1 antiserum. Bottom, densitometry
analysis of the autoradiogram shown above. Western blot and video
densitometry were performed as described in “Materials and Methods”. * P
< 0.05.
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Figure 4-3. Supershift of HNF-1-containing DNA-protein complexes
with anti-HNF-1 antiserum. Fao rat hepatoma cells were deprived of
serum overnight and incubated in the media containing 5-25 mM glucose for
the indicated period of time. Nuclear extracts were prepared and incubated
with a radiolabeled probe containing the HNF-1 binding sites. After 1 hr
incubation at room temperature, anti-HNF-1 antiserum (Ab) was added to
the binding reaction, followed by EMSA as described in “Materials and
Methods”.
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Figure 4-4. Effect of glucose on HNF-1 binding activity in Fao rat
hepatoma cells. Fao cells were grown to about 80% confluency and
deprived of serum overnight. Cells were then incubated for 24-120 hrs with
DMEM containing glucose of indicated concentrations and appropriate
concentrations of xylose to equalize osmolarity. Nuclear extracts were
prepared and subjected to EMSA as described in “Materials and Methods”.
A representative autoradiogram of EMSA is shown with protein-DNA
complexes containing HNF-1 are indicated by the arrowheads.
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Figure 4-5. HNF-1 and albumin protein levels were not affected by
glucose. Fao cells were grown to about 80% confluency and deprived of
serum overnight. Cells were then incubated for 24-48 hrs with DMEM
containing glucose of indicated concentrations and appropriate
concentrations of xylose to equalize osmolarity. Cytosolic proteins and
nuclear extracts were prepared and subjected to western blot analysis as
described in “Materials and Methods”. Equal amounts of nuclear protein
(top) or cytosolic protein (bottom) were loaded on each lane and resolved by
SDS-PAGE, followed by transfer to a PVDF membrane and probed with
antiserum against HNF-1 and albumin, respectively.
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